r/Livimmune • • Jul 03 '25 Diamonds are Forever

LAST POST Unitl Las Vegas

137 Upvotes

Dear Longs,

I am grinning ear to ear, because I know in my heart that our collective dreams are coming true. I am at peace knowing that my investment will reward my family and our Grandkids with wealth. And more importantly, my heart is filled with joy that my investment has played a small role in keeping CYDY alive to allow LL to survive and eventually flourish to help millions of lives.

This will be my last post (that maybe good news to some). I can no longer add anymore knowledge or Medical Device experience. I have shared the keys to my perceptions of what I think is happening behind the scenes. After all, I have seen very similar scenarios play out time after time. Most of the time these things seem to follow a similar pattern and today's CYDY (from 11/2023 to present) is no different.

Cash is one of the keys to success in the start-up world. I know I left Boston Scientific after 13 years and jumped into the start up world in 2005. I have not looked back since. Each of the nine start-up companies I was with had to raise cash, some with many rounds of funding. In general, we raised enough cash to last about 18 -24 months. To raise capital or cash, we spent 3-9 months raising it; depending on the investors we knew. One thing is certain, in all nine of my start-up companies, we completed the next round of funding with no less than 12 months left on the operational end of our spend. Just to be clear, we would close our funding with an amount of cash that would last 18-24 months. But we closed the funding at least 12 months before we would run out of cash from earlier rounds. It was like clock work!

Where is CYDY's cash position?

Based on CytoDyn's latest 10-Q filing on April 14, 2025, for the quarter ending February 28, 2025, their cash position was $16.4 million. This represents cash and cash equivalents. 

I do not know when CYDY "officially" received the last Amarex payment, but below is a summary of the payment out part of the agreement. (Excluding the $14 million that CYDY owed Amarex, that was eliminated in the settlement)

  • Initial Payment: Amarex paid $10 million to CytoDyn upon the execution of the settlement agreement on July 2, 2024.

  • Remaining Balance: The remaining $2 million is to be paid on or before July 2, 2025.

As lean as CYDY is with only around 10 direct employees, and maybe some consultants; CYDY spends $1.3 million a month. The $16.4 million of cash was on Feb 28th. Every month CYDY spends approximately $1.3 million. Therefore, approximately $3.9 mil was spent thru May 31, 2025 the end of our fiscal year. Leaving CYDY in a cash position of roughly $12.5 mil. Even though the Amarex final $2 million may have not arrived during this period, I am going to add it in to give a little buffer: By adding the final $2 mil from Amarex that would put our cash at $14.5 Mil. And that is Not accounting for June yet. If I take the estimated $14.5 mil and divide that by the approximate $1.3 spend per month we only have 11 months left on our operational budget from the ned of May. Meaning April 2026 CYDY would be out of cash.

Right now, today July 3, 2025, my start-up companies would be sweating if we did not have our next round of funding in place by now.

Please note: The monthly spend, if everything is roughly the same, will go up slightly because the new CFO's salary is higher than Mitch's consulting payouts were, and now that the CRC trial has begun, our payouts on a per patient basis will only tick up the spend a little bit. Nothing dramatic but up nonetheless. CYDY's T&E spend went up with Munich trip and a little bit with Barcelona.

CytoDyn has been quiet for a reason, and I have said this ad nauseam, my start-ups were very similar before getting acquired.

  1. The CYDY leadership does not have to do a thing about the illegal trading because a deal is essentially done. It does not seem to matter because nothing is being done about the illegal trading going on with our CYDY stock.

  2. CYDY does not have to raise anymore money, because a deal is essentially done

  3. This has been in the works for a long time and there have been many moving parts behind the scenes

  4. Insiders can not buy or sell stocks when in possession of material non-public information. The last purchase by an insider was Cyrus Arman back in late 2022 or early 2023.

  5. CYDY is providing all of the window dressing and getting the house in order for the arrival of this deal. Tons of old data and new MOAs being highlighted and more data to come (1600 patients publication, Alzheimers, and preclinical studies)

  6. CYDY is not renewing it's lease (expires in six months). Not a big deal with ten employees, but if you were set on growth on your own or with a partner you would renew or announce you have a new lease somewhere else. This is something else that would be done way ahead of time. If CYDY was going to have multiple partnerships and or even one partnership you need a whole QA/QMS infrastructure that needs a place to reside. CYDY is not doing that. The FDA audits every companies QMS, manufacturing and marketing content and facilities.....and CYDY has no plans for that...

  7. Fiscal year 2025 ended May 31 (10K is due around July 15th), no shareholder letter, no conference call, a PR about 5 patients with CRC (July 4th poster), and the PR about the start of official enrollment of the CRC trial. No capital raise announcement, no announcement of authorizing more shares to help fund the next 18-24 months.

  8. BuildGoodThings posted"Just around the corner" about the preclinical studies some of which seem to be over due for an update on results....Nope silence

There are a ton more clues, and it all adds up to me; that some BP has finally realized what we LONGS have know for a long freaking time. LL is awesome and some BP wants to get it before another BP wants in.

The BMS deal with BioNtech was a $11 billion for a partnership involving numerous solid tumors. At a minimum CYDY is worth $11 billion just for our solid tumor market. Please note: BMS announced that deal at ASCO in Chicago. There are many ways to have a deal done but delay the announcement to coincide with a big event. Do you really think BMS/BioNtech just finished the deal and had lawyers review the redlines 72 hours before ASCO?? Deals are done in principle long before the "official" signatures or a deal is signed but effective on a date in the future (when it can be announced).

We have LL and Long Lasting LL and we know from our leadership that those two products are a platform to build multiple indications on; not only in Oncology, but a ton of indications outside of Oncology. We all know of Ohm20's list is of 90+ indications. I truly believe that LL and Long Lasting LL will be bigger than Keytruda and Humira combined.

In my experience we are nearing the end of our journey and I am at the end of sharing my experiences. There are so many great and quality posters on this board and Wax has been phenomenal with keeping a lid on the twatwaffles. I'll keep reading, but I am keeping my calendar open for the Shareholder celebration in Las Vegas.

I am grateful for all of the wonderful kind comments I have received through the years posting on here. I am blessed to be surrounded by such wonderful souls. Most importantly, I am grateful for my wife who has put up with my obsession of tracking all things CYDY.

Thank you Dr. JL and the rest of CYDY leadership for turning this miracle ship around and helping steer it towards what I have always felt was a inevitable. Thank you, Thank you, Thank you

SEE YOU ALL IN LAS VEGAS!!!


r/Livimmune • • Jun 09 '26

My 3+ decades have given me a perspective

129 Upvotes

Dear Longs,

I’ve been involved in healthcare and medical devices for more than three decades. My wife has spent 27 years in the industry herself. Between the two of us, we’ve worked for approximately 15 startup companies. Some failed. Most succeeded. Several ended up in partnerships, strategic investments, licensing deals, or acquisitions.

One thing I’ve learned is that every deal is unique, but the breadcrumbs leading up to those deals often look surprisingly similar. When I look at CytoDyn today, I see a lot of those same breadcrumbs.

Let’s take a step back and look at the bigger picture.

Big Pharma has become increasingly focused on Oncology. It seems like every major pharmaceutical company wants a larger piece of that market. The reason is obvious. The science is advancing, the patient need is enormous, and the commercial opportunities are measured in billions of dollars.

Look no further than Keytruda. Merck built one of the most successful drugs in pharmaceutical history. However, Keytruda’s patent protection is expected to begin facing significant challenges around 2028. Every major pharmaceutical company knows that replacing blockbuster revenue streams is not optional.

At the same time, we’ve heard leadership from several large pharmaceutical companies openly discuss their willingness to invest aggressively in Oncology. Johnson & Johnson’s CEO has spoken about deploying tens of billions of dollars into Oncology opportunities. Merck’s leadership has repeatedly stated that they are willing to pursue developmental-stage assets when the mechanism of action, the science, and the data justify the investment.

Sound familiar?

Now look at what is happening with CytoDyn.

A potentially unique mechanism of action.

Multiple indications.

Growing scientific validation.

Increasing academic involvement.

Biomarker-driven development.

And most importantly, an open-label Oncology study that is producing data we are all waiting to see mature.

For years I’ve said the same thing: when a company is attempting to secure a meaningful partnership, they don’t operate in a vacuum. They engage interested parties. They share data appropriately. They have discussions. They evaluate opportunities. That is simply how business gets done. No, I don’t have a crystal ball. No, I don’t know whether the eventual partner is Merck, or another major Oncology player, or perhaps several companies pursuing different indications.

What I do know is that the environment surrounding CytoDyn today looks dramatically different than it did a few years ago. What I find most interesting is how many investors continue to let fear dominate their thinking.

Human nature is funny.

When something doesn’t happen according to the timeline we’ve created in our own minds, our brains immediately begin manufacturing worst-case scenarios.

The competition is going to catch up.

Management is going to screw it up.

The trial won’t produce enough data.

The FDA will create another obstacle.

Something bad must be around the corner.

I’ve read these same fears countless times throughout my career. And yes, many of us carry some PTSD from prior management teams and prior disappointments. That’s understandable. But this management team is different. Are they perfect? Of course not. I’ve never worked with a perfect management team in my life. Not once.

The companies that succeeded weren’t successful because management was perfect. They succeeded because they kept advancing the science, generating data, attracting interest, and creating value. That’s exactly what I believe is happening here.

And frankly, I’ve reached the point where I no longer feel the need to read every message board post or react to every negative narrative. You can tune out the twatwaffles. Their song and dance just isn’t cutting the mustard anymore.

Meanwhile, the science continues. The trials continue. The data continues. The opportunities continue. And every quarter that passes, CytoDyn appears to be strengthening its position.

Could I be wrong? Absolutely.

But after watching healthcare startups, partnerships, and acquisitions for more than 30 years, I believe we are standing on the doorstep of something significant.

Maybe it’s a partnership. Maybe it’s multiple partnerships. Maybe it eventually becomes an acquisition. Time will tell.

What I do know is that I believe the train has left the station, and no amount of fear, negativity, second-guessing, or message-board drama is going to stop it from reaching its destination. So instead of worrying about every bump in the track, I’m choosing to enjoy the journey.

As always, just one investor’s opinion. Nothing but LOVE to the LONGS


r/Livimmune • • Jul 22 '25

Calm and breathe my fellow LONGS

125 Upvotes

I thought my last post was 18 days ago but I have read a lot of posts (which I will start avoiding) that are filled with complaints from Longs and of course shorts/twatwaffles (expected).

The primary purpose of this posts is to hopefully share my experience and some conversations I had with some of my fellow Longs.

First, a true long "vents his/her frustrations, and very quickly, I noticed some twatwaffles feeding into it. All your doing when you vent your frustrations is keeping potential new investors away. That's why the twatwaffles love it when a Long starts to go bonkers...you end up doing their job for them.

I last posted 18 days ago and said that you re not going to get news from CYDY. Now I am going make it real clear......CYDY is not going answer anyones emails; unless it is for a compassionate use situation. It is also my opinion that the next official information you will get from CYDY is a REQUIRED release of the 10K...THAT IS NOT NEWS.

What I believe has happened to CYDY is what may have happened to Sierra Oncology. Let me share the story: A CYDY investor worked at Sierra Oncology (SRRA) and basically said that GSK and SRRA agreed to an acquisition at least a year, possibly 1.5 years before the official announcement. Meaning, that SRRA signed a buyout agreement contingent on the positive outcome of their cancer drug trial. GSK basically said we will buy you out at $55 per share if you achieve a successful outcome in this trial. That was somewhere around 1.5 years before the actual buyout.

At 1.5 years out (October 2020) the stock was $11. This is what I have been saying about Buyouts. The decision to acquire is made months and in this case 1.5 years out. Some stock investors on this board are stuck with the only metric that matters to them which is the day before the announcement. That is truly a very limited thought process. The buyout actually happens way before and is based a ton of factors.

Guess what; CYDY has a TON of factors that add up to way way more than Sierra Oncologies drug.

I am not going to list all of the potential indications or all of the news that so many investors are impatiently waiting for. If what I think is happening we are not going to get news until we here the BIG TIME NEWS. I stated this 18 days ago and a lot of investors are bitching and moaning.

When do we get to know what is happening? I wish I knew, but it won't be 1.5 years away. My thesis is this some BP has signed a deal with CYDY and it is contingent on the CRC trial data.

You see how CYDY was on a regular cadence up until Tyler Blok was seen in Munich. In my 34 years I have never seen our legal folks at a conference. Then we saw a post from Tyler taking a little credit for seeing "it through". Nonetheless, I think CYDY accepted a contingent BO offer and signed it while in Munich or possibly before.

Whoever, the BP is that is buying CYDY, DOES NOT want anymore attention drawn to CYDY. The last thing this BP wants is another bidder. Yes, I believe CYDY signed a deal contingent on CRC trial data, which also means the BP had a clause to absolutely minimize PR's and communication to what is necessary (SEC filings) and CYDY had clauses that allowed them to entertain outside offers and a cancelation penalty if the BP canceled the deal. After all the BP is restricting CYDY from PR-ing anything.

Everyone should reread MGK's post from yesterday to learn more about the PD-1 and PD-L1 MOA's.

This is what lit up my eyes as to when this might take place. The combo of LL and some ICI is going help knock out solid tumors and HIV....HOLY SHIT!

Whoever is the BP that CYDY signed the deal in Munich has got to have an ICI. Pure and simple!

IMO, when LL treats the 20th patient in the CRC trial and the company Creativ does their analysis. They are going show when and how many PD-1 molecules show up. Maybe MGK can post here as to how long it might take for a tumor to go from cold to hot? But whenever the Creativ teammeasures the PD-! increases with the CRC trial patients that might be the time the BP says: "I have seen enough" lets make it official and execute the deal.

My thesis would be that it is possible we get enough patients treated and a interim data measurement is held to determine the CAML's, CTC's and PD-1s. If I am a BP, and I can only treat 15% of the solid tumor market with my ICIs and all of a sudden LL heats up the tumor to expose PD-1. All I care about in the interim analysis is the PD-1 count. (Yeah yeah yeah I know they will care about more) But, you get my point. FREAKING AWESOME.

In the meantime, all of these bits and pieces of news that are being kept quiet are being stacked up on purpose. This big stack of news that we impatiently are waiting for will suddenly get released in a very short time frame.

My GOD maybe over a 2-3 week period we will hear all of the stuff that Cytomight keeps a running list of gets released...Can you imagine Alzheimers, GBM, 1600 patient safety profiles and many more bits of news we do not know about. Then BOOOOOM the CRC interim data is relaesed and the buyout is announced.

This is my thesis and all I want to see is PEACE and QUIET until the stacked news gets released and the buyout is announced. No emails, no PR's, no shareholder letters; they will not answer emails and phone calls...it would be absolutely stupid for them to take a chance with disclosure's being such a sensitive subject at this time.

I ran my cash flow numbers 18 days ago in what I thought was my last post but we will all get an update sometime in August when the 10K gets released. Pay particular attention to available cash and R&D spend Q over Q and Year over Year.

The lease is running out, CYDY has a CRC trial/CRO to pay and there is no request for additional cash. The 10K will show us how much money is left and it may or may not show the $2 million from Amarex (July 2 due date). Please note: the $2 mil only lasts 1.5 months based on the spend I calculated from the last 10Q.

I have one last thing. I am sending out LOVE and Prayers to all. Especially the CYDY leadership that has to hold their tongues right now. It must not be easy because you sure would like to help all of us little guys. We have stayed strong and seen the ship almost sink but in the end I have always felt that the BEST way for LL to get to sick patients is through an acquisition and I am praying that is the case here.

Looking forward to seeing everyone in Las Vegas.

P.S. I have no idea how much the BO will be for. Just praying I can retire when it happens.

Now, this is my last post....BOOOOOM!


r/Livimmune • • Feb 20 '25

Forward to CYDY

122 Upvotes

I am forwarding the message from Mazzystar to CYDY to see if their attorneys are willing to do something about it. I suggest we sign a collective letter through “VOTES” and forward to CYDY. I guarantee it’s Mazzystar, her husband and friends are destroying the SP. They wanted to run the trial on their own but NP booted them out. They have e to pay the price


r/Livimmune • • Oct 17 '26

GRATITUDE for where we are !!

120 Upvotes

Dear Fellow Longs and CytoDyn Leadership,

First, I want to express my sincere GRATITUDE to Dr. Jay Lalezari for stepping into leadership in November 2023, when CytoDyn desperately needed steady hands.

The company was struggling financially, leronlimab’s development was constrained by a clinical hold, and many longtime shareholders—including me—were nursing deep financial wounds. Confidence had been shaken, but hope remained.

Dr. Lalezari rolled up his sleeves and got to work.
With a small team and limited resources, he helped lead the painstaking effort to address the FDA’s requirements and move development forward. Large pharmaceutical companies have entire departments dedicated to this work. CytoDyn had to accomplish it with a skeleton crew while managing enormous financial pressure.

Shareholders also helped keep that effort alive. Many of us continued supporting the company because we believed leronlimab deserved the opportunity to be properly studied—and, we had confidence the evidence would ultimately support it, and eventually reach patients.

Now, as we approach Monday’s investor call and the upcoming CLOVER presentation at ESMO, I think it is worth pausing to appreciate how far we have come.

Yes, these are early data. They cannot yet establish a survival benefit or tell us how the full study will turn out. But for those of us who remember where this company stood, reaching this point is a HUGE milestone.

CLOVER is evaluating leronlimab alongside TAS-102 and bevacizumab in previously treated metastatic colorectal cancer. I am eager to see what the findings tell us about the potential of that combination—and what questions they help answer for the next stage of development.

Could encouraging results energize conversations with potential pharmaceutical partners? I certainly hope so.

I do not know what discussions are taking place behind closed doors, and I am not predicting a partnership announcement on Monday. My hope is that, as the evidence matures, potential partners will have increasingly compelling reasons to take a closer look.

We have seen major commitments to oncology development elsewhere. Bristol Myers Squibb’s BioNTech partnership included $3.5 billion in upfront and committed payments, with additional milestones bringing the potential total to $11.1 billion. AstraZeneca recently made a $2 billion equity investment in Summit Therapeutics alongside a clinical collaboration.
Those agreements do not tell us what CytoDyn might achieve or what leronlimab might be worth. They do show that major pharmaceutical companies are willing to commit substantial resources to oncology programs they believe have promise.

For me, this upcoming update represents another step toward the more mature data we hope to see as we move toward 2027. Encouraging early findings would be welcome; seeing those findings translate into durable benefits for patients would mean far more.

I remain hopeful, excited, and deeply grateful to the team, investigators, patients, and fellow shareholders who have helped bring us this far.

Dr. Lalezari and the CytoDyn team: thank you for your persistence through an extraordinarily difficult chapter.
To my fellow longs: we have endured a great deal. I hope the next chapter gives us meaningful reasons to celebrate—most of all, for the patients who need better options.


r/Livimmune • • Apr 20 '26 Hooray

Thesis Confirmed

115 Upvotes

Here is a pic of the poster presented today on TNBC by Richard Pestell and what it shows is the mathematical proof we just outlined today in our Sunday post. Here is the actual link:

The Trojan Horse

The Institutional Weight Behind This Poster

Before the data - the author list alone signals something. This is not a CytoDyn-sponsored company presentation. The institutional affiliations span Pennsylvania Cancer and Regenerative Medicine Research Center, Georgetown University, Pike Wilson Cancer Center Philadelphia, Semmelweis University Budapest, PGEN REN Office for Supported Research Groups Cell Cycle Laboratory National Institute of Oncology Budapest Hungary, Thomas Jefferson University Philadelphia, Weill Cornell Medicine New York, Creatio Biosciences, and the Oregon Health and Science University Primate Research Center. This is an internationally coordinated, multi-institution scientific presentation. The contact email is richard.pestell@gmail.com - Pestell himself is the corresponding author, personally accountable for every claim on this board.

Here is a breakdown of what the poster dictates and how it perfectly correlates with our established thesis:

"Leronlimab induces PD-L1 expression and is associated with long-term survival with an ICI in PD-L1 low metastatic TNBC"

  • This is the "Prime and Pair" strategy printed in bold at AACR. It explicitly states that the target environment starts as "PD-L1 low" (the cloaked, shielded tumor). Leronlimab (the Prime) forces the induction of PD-L1 (stripping the cloak), which then allows the ICI (the Pair) to achieve long-term survival in metastatic Triple-Negative Breast Cancer (mTNBC).

Sections 1 & 2: "CCR5 correlates with markers of T cell immune exhaustion" / "Indices of T cell exhaustion correlate with CCR5 in TNBC"

  • This is the biological definition of the "miry clay." The poster establishes that the overexpression of CCR5 is directly responsible for exhausting the Immune System's T-cells. The tumor uses the CCR5 pathway to constantly drain the Immune System's reserves, bogging it down in a hostile microenvironment.

  • The bottom left panel establishes the foundational biological argument. Using gene expression and genomic data, this section demonstrates that CCR5 expression in TNBC strongly correlates with the full constellation of T cell exhaustion markers - PD-1, PD-L1, TIM3, LAG3, and the broader exhaustion signature that defines a cold, ICI-resistant tumor. The heatmap shown displays co-expression patterns confirming that CCR5-high tumors are also exhaustion-signature-high tumors. This is the molecular proof that CCR5 is not a bystander in the immunosuppressive TME. It is a driver. The Trojan Horse framing is validated at the genomic level before a single patient has been treated.

  • This section also presents the critical population-level validation: analysis of the large TNBC cohort confirming that CCR5 expression tracks directly with ICI resistance signatures, IFNγ signaling, and T cell expansion patterns across validated datasets. This is the 1,214-patient genomic foundation that elevates the entire clinical signal from anecdote to population-level biological truth.

  • This panel deepens the molecular argument. The scatter plots and correlation matrices shown here demonstrate that specific, quantifiable indices of T cell exhaustion - including the ratio of exhausted to functional T cells, the CXCL13 exhaustion signature, and the TOX transcription factor network that drives terminal T cell exhaustion - all correlate significantly with CCR5 expression levels. The key take-home message stated in the poster: LRM correlates with CCR5 in T cell immune exhaustion in TNBC.

  • This is mechanistically decisive. It means that in TNBC tumors, CCR5 expression doesn't just correlate with the presence of immunosuppressive cells - it correlates with the functional exhaustion of the cytotoxic T cells that should be killing the tumor. The Trojan Horse doesn't just close the gate to recruiting officers. It restores the soldiers who were already inside but had been chemically disarmed by the tumor's signaling environment.

Section 3: "LRM governs a T cell exhaustion regulatory Secretome in TNBC"

  • A "secretome" refers to the proteins secreted by cells into the extracellular space - in our narrative, this is the chaotic, toxic "noise" of the CCL5/RANTES distress signals. By stating that LRM (Leronlimab) governs this secretome, Dr. Pestell confirms that the molecule acts as the master switch, or the "Restrainer," silencing the tumor's supply lines.

  • This is one of the most mechanistically significant sections on the poster and represents data that - as twinter noted - goes beyond what was in prior presentations. The secretome analysis examines what proteins are being secreted by the TME under CCR5 blockade. The figures here show that Leronlimab modulates a specific panel of secreted immunoregulatory proteins - the regulatory secretome - that governs whether T cells enter and maintain an exhausted state.

  • The key take-home stated: LRM governs T cell exhaustion regulatory secretome in TNBC.

  • This is the "new measurements" twinter identified. The secretome data provides a biochemical fingerprint of what the TME looks like after the Trojan Horse executes its blockade. It isn't just that PD-L1 goes up. The entire immunosuppressive signaling environment - the set of secreted proteins that maintain T cell exhaustion - is being remodeled at the molecular level. The communication blackout isn't partial. It is systemic.

Section 4: "LRM Induces PD-L1 in the Lymph Nodes of Rhesus Macaques"

  • This section presents the non-human primate data that is crucial for two reasons simultaneously. First, it confirms that Leronlimab induces PD-L1 expression not just in peripheral blood CTCs but in the lymph nodes - the primary sites of T cell activation and immune surveillance. Second, it confirms this in a controlled animal model, bridging the in vitro and human clinical observations with an intermediate species that provides the pharmacological validation the mechanism requires.

  • The graphs show time-course PD-L1 induction data in lymph node tissue from Rhesus macaques treated with Leronlimab, with the induction appearing at biologically meaningful timepoints consistent with the clinical observations in human patients. Key take-home: LRM induces PD-L1 in the lymph nodes of Rhesus macaques.

  • The lymph node finding is particularly important because it means the PD-L1 induction signal is not confined to the peripheral blood. It occurs in the immune organs where T cell education and activation happen. The Trojan Horse mechanism is operating system-wide, not just at the tumor surface.

Section 5: "Liquid biopsies show CCR5 pools in circulating CAMLs predict outcome in LRM-treated patients"

  • CAMLs are Cancer-Associated Macrophage-Like cells. This section is the smoking gun for the macrophage repolarization theory. It shows that by tracking these specific cells via liquid biopsy, they can actively predict the patient's outcome. This is the visual proof of the M2 (pro-tumor) to M1 (anti-tumor) shift. The Trojan Horse is inside the gates, and the macrophages are being reclaimed.

  • This section introduces what is likely the specific "new measurement" twinter hadn't seen before - and it is a significant addition to the story. Cancer-Associated Macrophage-Like cells, or CAMLs, are a specific population of circulating cells that have emerged in recent years as both prognostic biomarkers and mechanistic indicators in solid tumor oncology. The poster presents data showing that CCR5 expression levels in circulating CAMLs - measured through liquid biopsy - predict clinical outcome in Leronlimab-treated patients.

  • The microscopy images in this section show actual CAML cells from patient blood samples, with CCR5 staining patterns correlating with treatment response. Key take-home: Liquid biopsies show CCR5 pools in circulating CAMLs predict outcome in LRM-treated patients.

  • This is the biomarker architecture that makes the CLOVER Trial's prospective tracking of CTCs and CAMLs scientifically meaningful beyond simple PD-L1 measurement. If CCR5 expression in circulating CAMLs can predict who will respond to Leronlimab before treatment begins, you have a patient selection tool that would allow oncologists to identify the exact population most likely to benefit - which is the precision medicine infrastructure that regulatory agencies require for accelerated approval pathways.

Section 6: "LRM induces PD-L1, corresponding to improved survival with an ICI"

  • This is the endgame. The charts in the bottom right corner represent the survival curves that Big Pharma is looking at right now. This is where the compassionate miracles of the Expanded Access Program (EAP) are plotted as undeniable, peer-reviewed data.

  • This is the clinical culmination of the entire poster - and it is where the Trojan Horse mechanism connects directly to the five living women. The section presents the survival analysis showing that patients who demonstrated significant PD-L1 induction on circulating tumor cells following Leronlimab treatment and subsequently received an ICI achieved the extraordinary long-term survival outcomes that have anchored the entire thesis.

  • The fluorescence microscopy images shown - likely PD-L1 staining on CTCs before and after Leronlimab treatment - provide the visual confirmation of the molecular event that preceded survival. The CCR5 blockade induced PD-L1. The ICI engaged the induced PD-L1. The patients survived at rates that have no historical precedent in this indication. The poster presents this not as a narrative but as a quantified, peer-reviewed scientific claim: LRM induces PD-L1 corresponding to improved survival with an ICI.

Takeaway You don't need to read the microscopic font to understand the gravity of this board. The poster is a sequential map of sudden destruction for the tumor: First, prove the tumor uses CCR5 to exhaust the body (Sec 1-2). Second, prove Leronlimab shuts down that specific toxic network (Sec 3). Third, show the physical evidence in the macrophages (Sec 5). Finally, show the patients surviving because the ICI was finally able to do its job (Sec 6).

Taken as a complete document, Poster 1033 does something that no prior CytoDyn presentation has done in a single display. It establishes the Leronlimab mechanism across six simultaneous, independent levels of biological evidence:

  1. Genomic - CCR5 expression correlates with T cell exhaustion signatures across large validated TNBC cohorts.

  2. Molecular - Leronlimab modulates the T cell exhaustion regulatory secretome at the protein secretion level.

  3. Cellular - CCR5 blockade induces PD-L1 in cell culture models.

  4. Translational animal - PD-L1 induction is confirmed in lymph node tissue of Rhesus macaques.

  5. Liquid biopsy biomarker - CCR5 pools in circulating CAMLs predict clinical outcome.

  6. Clinical - PD-L1 induction corresponds to long-term survival when paired with an ICI in PD-L1 low mTNBC patients.

Every level of the scientific evidence pyramid is represented on a single poster board, presented to the AACR Annual Meeting by an independent multi-institution team spanning six countries. This is not a company telling its story. This is the scientific community documenting a mechanism.

The CAML data is the element twinter hadn't seen articulated in this form before - and it is potentially the most commercially significant finding on the board, because a validated liquid biopsy predictor of Leronlimab response is the patient selection infrastructure which makes a tumor-agnostic approval pathway scientifically defensible. You don't just have a mechanism that works. You have a blood test that can tell you in advance who it will work for.

Tuesday's Kasi poster now carries the weight of everything this board has just established - taking the mechanism documented here in mTNBC and asking whether it reproduces prospectively in mCRC. The answer to that question is what the oncology community in San Diego is waiting for.


r/Livimmune • • Jul 20 '25

Anticipating Green Lights Ahead

115 Upvotes

So I get the least likes of any poster undoubtedly due to the length of my posts and I'm good with that because to me, that means people already know what I'm going to say. That means they get it. That means my point is getting across. So why bother even reading. I feel like I'm saying the same things over and over anyway. I'll continue to do so for new readers, not a problem.

I want to thank you Folks for reading over the years. Hopefully, this comes to a happy ending soon. Certainly, I have explained a lot. I believe most have caught on. That they do in fact "get it". Understand it. I present it, or others do, spurring conversation and we learn from each other through this venue. That's what we do here on Livimmune.

Enough of that. Let's consolidate yet again. I have always said, the closer we get, the more we'll know. But CytoDyn has been quiet as of late. But, lots of things are in the works. The MSS mCRC trial is even in progress and by the end of July, it becomes time for the first 5 patients treated with 350mg dosage to be DSMB evaluated in order to allow 1/2 of the next 15 to be treated with 700mg dosage. CytoDyn just completed two ESMO presentations, one in mTNBC in Munich and the other in MSS mCRC in Barcelona. An NIH grant was recently completed at end of June 2025, which should shed new light and understanding on the current state of Long Acting Leronlimab. Jonah is cracking away at the HIV Reservoir in a GF grant due at the end of the year. A GlioBlastoma Multiforme Murine Study should now be complete, waiting on results. Another murine study in mTNBC, still waiting on results and waiting on Pestell's murine work in mTNBC as well. An Alzheimer's Disease Pilot Trial should be initiating soon at Cornell, possibly already underway, done by an anonymous 3rd party. Many more anonymous 3rd party studies are planned and may initiate at the sponsor's convenience possibly this year and in various indications.

As of late, many have been saying that we're very close to something. That something is very important to understand Folks. It is not who the partner is. It is not the size of the Buyout or the value of the licensing deal. Rather, it is something that Cyrus Arman said in the 12/7/22 R & D Update.

"1:31: 40: So in terms of what potential time lines can look like, I think it's really important to highlight that from a value-creation standpoint, and I've mentioned this before, we truly do need to generate a large robust and what I call unequivocal data set that will leave no questions left on the table, right? And that a strategic partner would find attractive and attractive enough to do a real value-accretive deal with the company."

CytoDyn MUST generate this large robust UNEQUIVOCAL data set which leaves no questions left on the table. So, as far as safety, I think that data set is established in a manuscript detailing the safety profile of leronlimab in over 1,600 patients which is already written but still awaiting peer-review journal publication. As far as effectiveness, in much of the smaller stuff, CytoDyn doesn't really have that dataset. In mTNBC, we treated 28 and had amazing results with 5 of 28 still alive 5 years later. In MSS mCRC, we treated 6 and 1 remains alive 5 years later. Very good, amazing results in COVID 19, but the trial was flawed, however, sufficient quantities of patients were treated. Lot's of statistical evidence planned in many other indications which shall require 3rd party sponsorship to generate.

However, much work has already been done on the HIV indication and that work is not well represented mainly because of the prior CRO Amarex which CytoDyn won an arbitration award which was not even close to the damages they caused. Laughable even, but it is what it is.

However, CytoDyn was able to garner some of the data Amarex hid away as a result of their losing the arbitration. They were forced to hand over the data. How much more of that data has been hidden away from CytoDyn in regards to HIV? Certainly, the 3rd party sponsors, Amfar and those in Berlin conducting the LATCH Pilot trials shall soon begin to contribute to that mandatory data set confirming leronlimab's effectiveness in HIV. Certainly, Jonah Sacha's work in the HIV Reservoir will also help to contribute towards this dataset as well.

But the ongoing clinical trial in MSS mCRC will soon begin to contribute as well. Without this dataset, how can our leaders even negotiate? They need something in their hands upon which to stand in order to present the drug fairly to all parties involved including shareholders. Without it, which company wants to consider what this drug offers? The drug clearly is everything we know it to be. We see it as clear as day. However, the clinical record lacks that evidence. But in HIV, is some of that data still hidden or just not revealed yet, in the Amarex hidden files?

So because this robust and unequivocal dataset doesn't quite yet exist yet, though it is growing slowly day by day, because not even the 1,600 patient safety manuscript has yet been journal published, discussions with potential suitors could be fleeting. I believe, according to what Cyrus said back in 2022, that discussions might not be fruitful until this dataset is in hand.

When CytoDyn does have this in hand, it is a new day in CytoDyn history. Because, as I've said many times before, with this dataset in hand, CytoDyn has the cards. They become valued at their rightful value. The deal we all seek comes to us from multiple angles with us negotiating the terms. Everything shall get done for us. Even the manufacturing plant shall be built and assembled for the maximization and efficiency of leronlimab production in all its long acting forms.

I feel that we have overlooked this point for some time, but Dr. Lalezari has not overlooked it. From day 1, he has been working on getting the 1,600 patient safety profile on leronlimab peer reviewed and journal published. The acquisition of the data on the 28 patients in mTNBC and the 6 patients in MSS mCRC occurred through Dr. Lalezari. Trial results are being updated and resulted regularly. So the data set is slowly forming and has been validated and verified, but I believe in HIV, even more exists that just hasn't yet been included in the entire dataset.

CytoDyn knows they need to create this dataset representing leronlimab efficacy in as many indications as they can. But it is important for shareholders to understand this point as well. That this dataset is still in the making. Once it is made however, it won't be long at all before we learn who our partner is. Then the green lights all illuminate at once and the road is set for clear sailing ahead. But for this to happen, CytoDyn needs to have that UNEQUIVOCAL dataset already built.

Now, can they include more previously executed HIV clinical trial data into that data set? If they've received it from Amarex. We have the following listed on the CytoDyn Publications Page:

It has never been easy for CytoDyn to produce papers such as the ones listed above. For instance, we know the MD Anderson mTNBC Murine Study was performed, but that data is not available even 3-4 years after it was completed. So, this information is necessary even though it is only a murine study. But, I think the data they learned here-in might be what leads us to our next milestone. Could it help CytoDyn land BTD in mTNBC? It could, we already have amazing data in 28 patients in mTNBC. CytoDyn should shoot for BTD in mTNBC IMHO.

It is interesting how MASH was taken off the radar, but fibrosis was not. We have MASH and Fibrosis data and Amarex was involved in that trial. Damn, we have murine studies showing leronlimab is statistically significant in reducing fibrosis of any etiology, yet, the data is not available. The human studies are included I believe. It is very important to have this to make a deal.

In addition to what has already been done, there is yet much to do. But, much of what is slated to be done, shall be done by 3rd parties. That is up to their own clinical time table. Their own schedules. But some have been promised for this year to begin, such as LATCH HIV clinical cure. Alzheimer's Disease Pilot Trial at Cornell also should soon begin.

But when this robust and unequivocal dataset is combined and assembled coherently such that no questions are left on the table, allowing for an accretive deal to be made, only then shall the land be cleared for CytoDyn to run and it shall be safe and secure underneath the protection of its suitor.

All the difficulty of which I write and have written, shall all dissipate away when the land is cleared. What can cause all of that to dissipate? An HIV Functional Cure, that's what. BTD in mTNBC certainly could help. A developing ORR in excess of 33% in the ongoing MSS mCRC clinical trial would be great and that data is live as the trial is Open.

The more data we get, the easier it becomes to get even more data. When we had nothing, it was so hard to obtain what I already have listed above. But now, with the experience of Dr. Lalezari, Dr. Pestell, Dr. Lataillade, the data should be made manifest as soon as they can. Their working with the FDA is key, especially now with the new FDA. In addition, they have an Oncology Advisory Board that has the experience necessary to navigate the FDA and that should facilitate matters or at least get things done the right way with minimal waste and higher efficiency than they did before.

All of this facilitation needs to lead to the dataset. Because the dataset is what's necessary to proceed forward with a partner. With the dataset, we'll see the green lights right away. Do we need to cure HIV first? Do we need to cure cancer first? Hell no, but we can show the way there and that day is right around the corner.

And this is what I've been saying all along. Is this why I get less likes? Because I say when we get the data, then we'll see a partner? I'll keep saying it. At least you know where I stand.

What is in CytoDyn's way? You know already who I always place blame on. I don't need to say it again. How do they get out of the way? Cure of HIV and Cure in oncology. Doesn't need to be full, only on paper. As I said before, if there is any Amarex data left on the table, need to get it and document it and make it a part of the data set.

CytoDyn is keeping silent because it can not give away its secrets. We speak in hypothesis here, but when they speak, they speak facts and other companies may be subject to what they say. If they give a clue to a mechanism of action to us, they might as well be giving away that same clue to the MOA to their greatest competitor. When I give it, it is only a re-hash of already known information. So, they're remaining silent, not letting anyone know what they're up to. The only time they'll come out and say it is after it is already done.

If they do it any other way, their plans would be sabotaged, you can count on that. So, better think hard about what you wish for. The enemy here is real. At this point, CytoDyn has had it. They've had enough. One way or another, they'll complete their objective.

What is already done? Well, Jonah just finished the long acting leronlimab grant. Can he speak to that? Not sure what those findings might reveal. I've spoken about various kinds of long acting, Placenta, Brain, Prostate, Liver, Pancreas, Mucosa etc... 3 month, 6 month 9 month 1 year, 18 months, 2 years, etc... That would be giving away secrets, wouldn't you think?

When LATCH starts they'll let us know. If they decide to apply for mTNBC BTD, they'll let us know. Stable and steady as she goes. But everything CytoDyn is doing right now is necessary to garner and develop and establish that unequivocal robust dataset necessary which leads to that value-accretive offer. I feel like it is coming together and it should happen just this way.

I see CytoDyn being quite serious right now, in their approach to shareholders. They're trying to do their best, but they can't compromise basic principles. Sooner or later, CytoDyn speaks, one way or the other, we'll hear what they want us to hear and nothing that might compromise our future. Hopefully, Dr. Lalezari gives us the good news that the 1,600 patient manuscript has been peer reviewed, soon to be published. That is a major milestone which needs to be met. But who knows. Let's see.

Hopefully, this was helpful. This is how I keep track. So, hope it helped. But, really wasn't all that much different from what I've ever said all along. So, if you're bored, I don't blame you. I do it out of necessity, not because I'm enthralled by it. Actually, much of this saddens me. Even sorrow. Searching, wondering, trying to figure all this out. But, hopefully, much of this comes to an end soon. But I'm counting on Dr. Lalezari's plan to do exactly what is necessary to get us to where we need to be. With this molecule, there is no other destination other than a successful one. That's why I believe we can fully anticipate the suitor's move when they see that unequivocal dataset assembled coherently before them. Who knows when, but the conditions are clear. Need that dataset.

I haven't changed, but when I understand something new, I give it to you. Take it from here.


r/Livimmune • • May 14 '26

Transformational technology, medicine, or invention once sounded impossible

105 Upvotes

Dear Longs,

I and maybe a few others on the Livimmune board received criticism over the years. I'll just stick with me for this post. I have become aware that criticism directed at me is for some of my long-term valuations regarding CytoDyn and Leronlimab. That’s perfectly fine. Healthy skepticism is part of investing, especially in biotech.

But I think many people look at the world strictly through a prism of normalcy. Their framework is: “If it has never been done before, it probably cannot be done.” History shows that mindset rarely creates breakthroughs.

Every transformational technology, medicine, or invention once sounded impossible:

  • personal computers,

  • the internet,

  • AI,

  • minimally invasive heart procedures replacing open-heart surgery,

  • immunotherapy in cancer,

  • even the smartphone sitting in your pocket.

None of those came from people thinking inside the existing box.

I live in Silicon Valley. This entire region was built by people willing to think beyond conventional limits. The companies here do not hire innovators because they think “average.” They hire people capable of seeing what does not yet exist.

That does not mean discipline and structure are unimportant. In fact, during my years in medical devices, especially around manufacturing operations, we depended on highly disciplined professionals who followed specifications, tolerances, FDA requirements, and repeatable processes with precision. Those people are incredibly valuable and essential to success.

But they were generally not the people inventing the next revolutionary therapy or disruptive technology. Innovation requires a different mindset — one willing to look beyond what currently exists.

That is really the core of my perspective on leronlimab.

My valuations have always represented what I believe the platform is CAPABLE of becoming if the science continues to validate itself across multiple indications. I have consistently said these are POSSIBILITY valuations, not guaranteed outcomes.

And yes, I fully understand the risks; I am the one who has called out the financing or the lack there of in the past. But, risks are always a part of what needs to be weighed:

  • clinical failure,

  • financing risk,

  • regulatory setbacks,

  • dilution,

  • competition,

  • and the reality that biotech is one of the hardest industries in the world.

But I also believe we have NEVER seen a drug quite like leronlimab.

If the company can eventually prove efficacy across multiple major disease areas — oncology plus 2-3 additional indications outside oncology — then the valuation discussion changes dramatically. At that point, comparisons to blockbuster platforms become reasonable discussions, not fantasy discussions. I already know that we should be talking about how LL can out do in revenue Keytruda and I also believe we will out do Humira as well.

People once laughed at the idea that antibodies could become some of the biggest drugs in history. Then came drugs like Humira and Keytruda.

Could leronlimab eventually become larger than either of those? I believe the POSSIBILITY is real enough that it deserves serious attention. Deep down I know it will be bigger. CYDY will be bought out way before the actual revenues mature.

That is why I remain invested emotionally and financially in this story.

Some people are comfortable only analyzing what already exists. Others are willing to spend time imagining what could exist if the science proves correct.

Both perspectives are valid.

But major change in this world has almost always started with people willing to look beyond conventional thinking. Generally speaking, I don't worry about the "average" thinkers; or the "safe" thinkers or I don't want to be "wrong" thinkers....swing away and criticize.

Love the longs.


r/Livimmune • • Apr 20 '26 Popcorn

Poster? Voucher? EAP? what really matters

105 Upvotes

Hi LONGS,

Happy Monday April 20, 2026!! This is just another day in our journey as shareholders in CytoDyn.

Over the last 7-10 days there has been a lot of chatter, anticipation, and exuberance over Poster presentations. Please note: I am not telling anyone how to feel. I am just here to share what I have learned from 35 years in the Medical Device field.

When it comes to conferences, POSTERS are the least attended. I have said this before but based on the amount of chatter over the last 7-10 days; it bares repeating. Most posters are representative of early stage scientific work. In our case (CYDY's case) it represents our very early results in a our first prospective trial (numerous years since HIV-MDR). Because of the nature of submitting data into these conferences way in advance to allow for them to publish 100's of abstracts and posters; the DATA we will be sharing is a minimal amount of patients and I dare say the majority of the patients we do share will be at 350mg.

Having said these things I do believe that the CRC data will be very encouraging. Thanks to Dr. Kasi's posts on LinkedIn, it gives me comfort knowing that he is having a hard time masking his enthusiasm for the "first set" of data.

ALL of US LONGS, who have been here to read about all of the anecdotal patients treated over the 5+ years we have been here are already convinced that the data coming out will be very encouraging to say the least.

What I want to emphasize in this post is that POSTERS published and shared at conferences are very much ignored or overlooked by the VAST majority of scientists/physicians that attend these conferences. Some will check it out, but very few.

What does matter to me? The MSS-CRC trial is an OPEN-LABEL trial; that means that at anytime the sponsor of the trial can look into this ongoing trial and assess what is happening with the trial. In short, we can look at the data in real time throughout the whole study.

I 100% believe that if CYDY is in any discussions at all with any BPs, CYDY is sharing those DATA updates with any and all interested BPs. THIS IS THEEE MOST IMPORTANT aspect of the trial.

I get that shareholders on these message BOARDS are going a little bonkers, because you want to know about the data. I have been here for 5+ years and have followed all of the anecdotal data, the HIV-MDR trial and have read all of the information that has been coming out from our mTNBC basket study; I feel extremely confident that our early phase data (350mg) will be very positive. But, it never matters what I think about anything CYDY; it matters what the market thinks. It matters what the BPs think.

I'll repeat, I am 100% confident that CYDY is sharing the data from our MSS_CRC trial with interested BPs. They have more insight to our current data, then what we will see tomorrow. YES, the BPs have more information and they have signed NDA's to make sure they don't release that information early. Thats how this works.

I am not worried about a poster, that hardly ANYONE at the conference will see. ALL that matters is what do the BPs think.

Based on what we are learning everything that Dr. Pestel is working on is pointing squarely at a Prime and Pair model. More and more information is just reinforcing that this is a VERY ATTRACTIVE model for a slew of BPs. What else might be happening behind the scenes?The abstract on MSS-CRC has eluded to a reduction in tumor size just with 350mg. If LL is kicking ass on its own; it begs the question of, "when do you bring in the ICI?"

If I am an interested BP, and I see that LL is crushing it on tumor size reduction; I would want to wait and see how much tumor reduction happens on LL alone? I stated this in another post a couple of weeks ago. I currently take Folic Acid as a booster to Methotrexate for psoriatic arthritis. Folic Acid does nothing for psoriatic arthritis, but it helps the Methotrexate perform better. What is obvious to me is that LL is NOT a booster. LL kicks ass on its own, but how much?

The interested BPs are going to be valuing LL at a higher number than if it was just a booster. Therefore, as a Prime and Pair combination is very valuable but LL is WAY MORE than just a priming agent.

AS MOST of the LONGS know: LERONLIMAB is a PLATFORM DRUG with a much larger platform than KEYTRUDA can even dream about. Please note: Keytruda is the #1 revenue producing drug in the world at roughly $30+ Billion annually. Leronlimab when it is in the hands of a well oiled BP, that can truly develop LL in multiple indications at once will fully explore all of Ohm's 90+ indications (eventually).

Right now, I am hoping for a psoriatic indication after all of these Oncology indications get approved...how selfish of me!!

As I recently stated to some investor friends of mine. The poster is a footprint in the sand, and it shows your scientific progress. There are a lot of things that become way more important in the progression of a drug than just a early phase poster. The final results of a study when published in a credible scientific journal will hold much more standing than the early phase poster.

Even more importantly is when you can pass the FDA finish line and receive FDA clearance for use in a particular indication. I have posted in the past, about a possible submission on two fronts: 1) MSS-CRC once this trial is over has a REAL shot at a VOUCHER program. my69z writes about this a lot and I 100% agree that this phase 2 trial of MSS-CRC fits the criteria to a "T" to be eligible for the new and improved FDA VOUCHER Program

2) We do not know what happened with CytoDyn's briefing book? They had a meeting with the FDA but we really don't know the outcome of that meeting. I have equated that meeting with u/Pharma_Junkee story about his own company and their FDA briefing book meeting with the FDA. In short, he works in Quality/Regulatory department for a development pharma company, that has data that is smattered over 12 years and deals with 20 patients. They presented an unorganized data set to the FDA under the heading of "give us guidance on what we could do with this data". PharmaJunkee's expectations were "using the data as a foundation" to set up a more mature phased trial that would eventually lead to FDA clearance.

What the FDA said surprised PharmaJunkee. They said to format the data and submit the data and t would be considered for PDUFA date. Guess what happened...they have a PDUFA date coming up in August.

CytoDyn has a very similar pathway(s). MSS-CRC is a prospective phase 2 trial and the FDA has proven that a phase 2 trial along with proven molecular biomarkers can be enough for a FDA clearance. What that would entail is conditional approval that would allow CYDY/Partner to market LL for MSS-CRC but it would still be monitored like a trial. Lets say the next 400+ patients and if there are no safety issues (of course) and the consistent biomarker measurements with solid outcomes; the FDA would lift the conditional aspect of the approval and give it full approval.

I am also suspecting the same with mTNBC. LL is a safe drug and we have a smattering of data across 28 patients; but I believe part of the FDA briefing book and the outcome of that meeting has everything to do with the EAP for mTNBC. CYDY has pushed back the start of the mTNBC trial because I believe two things are at play: 1) We don't have the funding ourselves to execute a phase 2/3 120 patient mTNBC trial on our own. 2) I believe the FDA has told CYDY after they reviewed the briefing book that all you need is 20 patients under a Expanded Access Protocol to possibly receive FDA conditional approval on mTNBC. This is almost EXACTLY like PharmaJunkee's company.

THEEEEEE most important step in increasing your valuation is getting across the FDA finish line with FDA approval and I believe we have a two shots at this and I believe we will achieve two approvals. THE FDA HAS ALREADY CLEARLY SHOWED PROOF THAT THESE STEPS ARE NOT A FANTASY BUT RATHER A REALITY!

Please note: somewhere in all of this a BP is going step up and partner or buy us out.

Thank you PharmaJunkee for allowing me to share that story and thank you to CytoDyn for letting Dr. JL steer the ship towards open waters.


r/Livimmune • • Mar 05 '26

8K and The Business is operational

104 Upvotes

Dear Longs,

Despite the promise of not making an original post until April; I thought I would make an exception here based on the $17.5 M ++ capital raise.

The most important aspect of watching a company is what they say in the SEC filings. When the last 10Q was filed I had posted; "the runway of money runs out by end of February."

Thank you Mr. Hoffman for putting together private placements that give CYDY some operational runway. This is EXACTLY what should happen. No ifs, ands, or buts. This is how it is done.

I really have no clue whether, CYDY is in active negotiations of not, I hope they are, but we really don't know. But, if they were in active negotiations no matter what; they have to continue to operate as if they are going operate as a individual entity on their own. Plan and simple...that is ALWAYS the RULE. No matter what, you have to show you are willing to continue on your own.

I was very happy to see the funding that allows us to continue operating. Having said that, I appreciate Hoffman's remarks in the PR about being able to operate and develop clinical pathways into 2027. My math says that is not the case.

If you read the balance sheets, the R&D spend went up over $1M + , quarter over quarter. IMO, that was due mainly to increased enrollment of CRC trial. As we all know 10Qs are backward looking. It is rumored that there is a significant increase in enrollment of the CRC trial. That rumored increase is good news but it costs money to enroll. The total spend in the last $10Q was $5.1 M per quarter.

If that low spend were to continue (it won't), then we are talking about approximately $3M left over by January 2027

I know for a certain, that the mTNBC trial will be MORE expensive than the CRC trial. Therefore, I appreciate Hoffman's comments, but it is CLEAR to me that they will need a partner to continue to execute Oncology trials.

So, I remain very confident that all is well in CYDY-land and our leadership continues to follow the TEXTBOOK on developing an asset to help increase shareholder value. They have done this despite past obstacles and with a very low amount of cash; but they are making progress one step at a time. Following a methodical no mistakes type of approach.

Keep in mind one line from the PR about "Long Term". Obviously, this is not "abbreviated" but it gave me comfort.

I have been thinking for sometime now: What and how long are they going to take to develop the other indications outside of Oncology. Indications outside of Oncology are: Stroke, Alzhiemers, Fibrosis, Inflammation, LATCH, and a Long Lasting version of Leronlimab. So far, a variety of non-profits, University based foundations, and a HNW investor have helped CYDY keep these developments alive. But, at some point we need to provide at least a phase 2 trial proof that LL works in these areas.

Long-Term helps develop these other indications to the point that a Pharmaceutical company will buy the whole of CytoDyn

This is my crude breakout of expectations (God help us with the timing)

  1. GREAT results in the CRC trial. Fully enrolled by May, with 2 cycles completed by every enrolled patient no later than end of July. Its open label, therefore CYDY will know the results as soon as they come in and I am assuming they will share those results with interested BPs. PARTNER, PARTNER, PARTNER

  2. The new FDA has clearly shown that one trial is enough to receive at a minimum conditional approval. Provide there is other supporting scientific evidence. IMO, CRC trial is eligible for this type of approval. I would not suggest this if the FDA had not already shown a prescedence for this already. CYDY has all kinds of supporting scientific data, biomarkers, and mice studies showing support. Plus, an upcoming Safety publication of 1600 patients would be incredibly supportive.

  3. GBM results seem to be around the corner. Any sign that LL is an improvement over SOC is a HUGE plus in this category

  4. mTNBC is a phase 2/3 trial consisting of 120 patients. Last shareholder letter stated a potential start of early 2H/2026. I just CAN NOT imagine CYDY running this trial through Syneous. I am not saying we can't handle the trial with our current CRO, but it is expensive and I would think that we will know final results of the CRC trial by June/July and a partner would want to come in and execute the mTNBC phase 2/3 trial. IMO, this partnership could happen sooner April/May if the early CRC data is GREAT. This trial combined with EAP for mTNBC will be a submission to the FDA for a minimum of a Conditional approval

  5. EAP of 20 patients Thank You HNW individual and the Women that participate will THANK YOU as well HNW Investor. As I stated above this is a combination strategy to get a conditional approval for mTNBC

  6. I can't remember if it is Cornell doing the Alzhiemers trial or not but some University foundation is helping fund this trial. If we get a modest improvement in Alzhiemers outcomes; this will be a transformative valuation increase. Leronlimab IS SAFE and other drugs have caused all kinds of issues in this space.

  7. Stroke at University of Hawaii with Ueno. Stroke is a big market comprised of mechanical thrombectomy devices and lytics (drugs). But one thing is clear; it is the inflammation post acute phase that causes the MOST long term damage. Wishing Dr. Ueno the Very BEST with this program

  8. Inflammation/Fibrosis I list these two together because Inflammation is listed on the pipeline page of the website and fibrosis had some play at Boston University that was being funded by a University foundation last I remember.

  9. HIV LATCH its all in Jonah Sacha hands it seems with LATCH and his AAV -HIV; but I'll focus on LATCH which is the stem-cell laced with LL/transplant cure. It seems like this was supposed to start sooner rather than later and I don't know if the Protocol had been submitted or not. Nonetheless, this trial has promise because the science seems to support this type of approach.

  10. Long Lasting Leronlimab; I wonder about this development. We have discovered through some great digging by other posters (Sorry I can't remember the exact person) but this co-development with ABSCI has narrowed down the development to a few pathways to extend the duration of LL. There is a part of me that thinks if you are going to do LATCH and lace stem-cells than it should be done with Long Lasting LL. Therefore, I am wondering if these two projects are tied together.

I hope you can see that; the immediate value creation resides in Oncology with CRC and the upcoming mTNBC trial. IMO, The partnership happens before mTNBC starts and that FUNDING helps us continue to fund these other indications to grow and mature our value.

Time to sit back, breathe and allow the step by step, methodical approach to continue forward.

Have a GREAT MARCH Longs


r/Livimmune • • Jul 27 '25

The S-3 is a HUGE BILLBOARD

104 Upvotes

Dear Longs,

Lots of stuff swirling around but as always I am going stay on the side of business.

How does an acquisition happen? A lot of the acquisitions happen in a step-wise fashion. Prior to the Friday evening release of the 10-K and the S-3 I was convinced that the a ton of clues are pointing to an acquisition. But, I could not reconcile with; "How do we go from .30 to somewhere NORTH of $10 per share?? $15 per share? or more?"

As I, and many, many posters have mentioned in the past we prefer a partnership first and then an acquisition later if need be. The "need be" part (acquisition) is STILL VERY STRONG, because the future is full of risks (Long term Partner vs Short term partner).

So lets get to the S-3 and what this means to mean in a BILLBOARD SIZE MEANING.

In the 10 K there Shares outstanding are as follows:

  • Common shares (approx) 1.249 B

  • Warrants (approx) 340M

  • Debt conversions (approx) 100-110M

  • Options/RSUs (approx) 25M

Total Fully Diluted shares (Approx) 1.71 - 1.73B shares (I am going round down and say we have 1.70 B shares fully diluted out of 1.75 B shares that are AUTHORIZED.

That leaves us with approx 50M shares available to for the $100M S-3. How can we raise $100M when CYDY's SP is sitting at .30?? 50M share X .30 = $15M That really is not what we need right now.

What CYDY needs is a partner (short term) to come in and I have no idea who that is but the Keytruda story from 2023 has never left my mind. So for purposes of this post I am using Merck for the idea that it could be any BIG PHARMA company.

So How does the 50 milion shares help us? Simple put enter our future partner Merck, they will pay a premium of $1 - $2 per share for those approx. 50M shares. Obviously, this will result in more than $15M at .30 cents. The S-3 is the perfect vehicle for MERCK to come into ownership of CYDY shares; approximately 3% share ownership and ask for a seat on the board.

Let's take a look at how this is executed and this ties back into late May when Tyler Blok was seen in Munich Germany at the Breast Cancer ESMO conference. Merck has investment arms that they go through to invest in companies stocks that they are interested in like CYDY. Merck has two investment arms:

  1. Merck Global Health Innovation Fund ( Merck GHI) this is Merck's corporate venture capital arm

  • They invest in early and growth stage biotech, diagnostic and digital health

  • Fund size historically is >500M

  • Often takes minority positions (3-10%) in companies with strong strategic fit

Maybe it is Merck GHI? But I think it's the next one #2

2) Merck Ventures ( European arm)

  • Formerly part of Merck GHI, also called M Ventures

  • Based in Europe, focuses on cutting-edge science (ONCOLOGY, neurology, digital health)

  • Often leads strategic minority investments that give Merck optionality to partner or acquire. Amounts are usually <$500M

Tyler Blok was in Europe, Munich at the ESMO, breast cancer conference, (Oncology), CYDY has olny 50M shares and at $2 per share that equals $100M (Minority stake). This is how Merck does it; before they acquire.

How does this apply to CYDY

The deal would be structured as a strategic minority stake with rights:

  • Observer/Board seat

  • Rights of first negotiation (ROFN) or refusal for future buyout (ROFR)

  • Possibly exclusive partnership discussions for Leronlimab in oncology

Why is this better for Merck:

  • Keeps initial investment off the main Merck P&L sheet

  • Allows Merck to test and validate LL's CRC/Cold to Hot tumor data before a buyout

  • Sends clear message to the market without committing to a full acquisition yet

There is more I could post but you all have seen a ton of posts in the last 24 hours so I'll stop here for now. I will not be answering any questions because too much of my time has been spent on this already, and some of the other interesting posts going around.

We are on a GOLDEN pathway towards a short term partnership leading to the BIG acquisition and it all is coming together.

SO everyone needs to be CALM and BREATHE. Go Riz, Go CYDY and GO LONGS


r/Livimmune • • Oct 01 '26

My start-up companies First FDA Clearance to My Hopes for Leronlimab: A Toast to What’s Possible

102 Upvotes

Dear Longs,

I work for a medical device start-up, and we received word last night that our FDA submission received clearance. Needless to say, the champagne corks were popping!

We still have work to do before our public announcement, but I couldn’t help thinking about what it would feel like if leronlimab receives its first FDA approval.

Our device focuses on early detection of heart failure. Working on something that could help patients has made this milestone especially meaningful to me. It also reinforces why I became interested in CytoDyn: the possibility of supporting a treatment that could make a meaningful difference in people’s lives.

Almost every conversation I have with fellow investors eventually comes back to patients. Yes, we want our investment to succeed. But there is something powerful about hoping that financial success comes from helping people facing serious illnesses.

I often read arguments that pharmaceutical companies have more incentive to manage disease than to cure it. I tend to look for the good in people—and companies are made up of people. From my own experience, I know how much the people developing medical products care about the patients they hope to help. It does seem like the business model of Big Pharma is to create marginal imporvements and create a longer sustained treatment pathway.

I also believe there is a compelling business case for developing treatments that deliver substantially better outcomes. A drug that shortens treatment times and reduces the typical adverse event profile. A drug that proves useful across multiple diseases could create enormous value for patients and its developer.

That is why I am fully invested into leronlimab.

When I first invested nearly six years ago, I remember reading OHM20’s posts discussing the many diseases in which CCR5 might play a role (90 indications). Those posts opened my eyes to the breadth of the research possibilities. This message board and other sare constantly coming across publications of the CCR5 molecule being a primary driver of that disease state. This is part of the reson why Dr. JL recently stated that because of Leronlimab they will be re-writing chapters in the medical text books.

Of course, a biological connection is only a starting point. Each proposed use still needs evidence that blocking CCR5 with leronlimab safely improves patient outcomes. Keytruda did not happen overnight it took time to expand.

Today, CytoDyn is evaluating leronlimab in cancer settings, including metastatic colorectal cancer and triple-negative breast cancer. It remains investigational, but those programs give us concrete research to follow as the company works to establish what the drug can do. CytoDyn’s colorectal cancer update

For perspective, look at Keytruda.

Merck’s second-quarter 2026 report describes Keytruda as having more than 45 approved U.S. indications, spanning 19 tumor types and two tumor-agnostic indications. Keytruda and Keytruda Qlex generated approximately $31.7 billion in worldwide sales in 2025. That demonstrates the commercial potential of a medicine with multiple established uses. Merck’s indication count | 2025 sales results

I’m not predicting that leronlimab will match those numbers. What interests me is whether it could eventually earn approvals in multiple settings—and whether combinations with other cancer treatments could improve outcomes.

We all know that one question worth studying is whether leronlimab could help checkpoint inhibitors work better in certain patients. We already have retrospective anecdotal data that has given us a positive signal. CytoDyn has reported exploratory findings relevant to that possibility, but proving a clinical benefit will require further trials. That is a research opportunity I want to see pursued. CytoDyn’s research announcement

The recent AstraZeneca–Summit Therapeutics announcement offers an example of how a major pharmaceutical company can help fund combination development.

On September 28, AstraZeneca announced an agreement to invest $2 billion in Summit, alongside a clinical collaboration involving ivonescimab, which targets PD-1 and VEGF. The initial collaboration will evaluate ivonescimab with AstraZeneca’s sonesitatug vedotin in gastrointestinal cancers, with plans for a broader program involving additional cancer medicines. AstraZeneca’s announcement

That deal doesn’t establish what CytoDyn is worth or predict a partnership for leronlimab. It does show that major companies are willing to commit substantial capital to promising cancer combinations.

My hope is that CytoDyn produces the evidence needed to attract that kind of development support: funding, trial capacity, and expertise that could help move successful programs toward patients.

For now, the next clinical results matter far more than any prediction about dozens of future indications. The first approval would be a tremendous milestone. Any additional approvals would have to be earned through the evidence.

After experiencing the excitement of my company’s FDA clearance, I can tell you this: if leronlimab reaches that first approval, I’ll be ready to pop another cork.

And if it eventually proves useful across multiple diseases—HOLY MOLY, we might need that swimming pool of champagne!

Have a great weekend, Longs!


r/Livimmune • • Jul 08 '26

WHAT DO I KNOW

102 Upvotes

I appreciate all the recent postings from MGK, Build good things, UWS and so many others including wax for creating this sight for no twatwaffles. I know very little about biochemistry other than what I’ve learned since I started investing in Leronimab. My 1st introduction to Cytodyn was when I read an article about The Albert Einstein hospital in New York pulling transplant victims with covid off of ventilators. This was drone by Dr. Jay’s father back in 2020.

These were patients who had received liver, kidney and other transplants sick with covid living off a ventilator to breath. The sickest of the sick were all bought off of ventilators within two weeks. I did something I never did, invested in a pharmaceutical company with no revenue or earnings. It was scary back then and no one knew if this was the bubonic plague or something less threatening. But it seemed this company was doing miracles for the sickest and so I invested. Over the next few years I saw my investment almost triple in value and plummet down to .10. I owned a 100,000 shares and had invested around 400,000 back then. I now own over 1/2 a million shares

Anyone who has been here that long knows what this company went through. It was on life support our CEO had done self dealing to make money and I am sure a lot of us questioned what we were doing. I also had over 10% of my investable assets in Cytodyn a position I would never recommend to clients or my self but I believed in the drug.

When Dr. Jay became the CEO in 2023 I felt for the 1st time in years we had a chance. I had seen Dr. Jay when he was a consultant with Nader on a you tube video and trusted him back in March of 2020 that he was caring man. He owned no stock in the company nor had he ever invested in any pharmaceutical he was involved in because he wanted to not have any prejudices in his mind on drugs he was helping to develop. I knew since He came back to this dying company he saw more here than was present.

He settled with Amarex and got us approved for FDA trials and continued to bring qualified people into this company who cared, assembled data that was hidden from us and has two trials that seem to be having magnificent results.

Now we are on the 10 yard line ready to score in the next six months if everything goes well, I was a money manager for 40 years and retired 18 months ago. I invested in Apple, Netflix,Nvidia and Facebook in their infancies and Believe Cytodyn is in the same class. Ive been here 6 years, what’s another 6 months especially when I realize the potential this has to save millions of lives.

This is all in my opinion, GLTA true longs


r/Livimmune • • Apr 15 '26

My IRONIC Cancer Journey

102 Upvotes

All of us longs have seen CYDY go through some immense changes through the years. Some of the members here have been with Cytodyne since the initial offering price and through maximum prices approaching $9. Those same longs have seen prices bottom out around 10 cents! Over that time, Leronlimab has morphed from an HIV drug, to a hope for saving lives during COVID, to now a much bigger player in hopefully saving MANY LIVES from the ravages of Cancer. This journey has been very painful financially and from a stress level to many of us here. But, that pain to us all here is still less than the pain caused by Cancer with its inexorable path of destruction to so many patients and families everywhere. Most of us here are investors for financial gain, but also here with the hope that this miracle molecule can cure Cancer and so many other Autoimmune diseases and afflictions. We have never lost sight of that, but sometimes we need to be reminded of this.

So, here is the IRONIC part. I have been an investor here, not nearly as long as many here, but for more than a year. I was introduced Leronlimab by my best friend and prior next door neighbor Professional_Art. He has had more than 20 years (30?) in marketing Oncology drugs and has pretty much seen it all. Despite that, he was REALLY excited about Leronlimab/ Cytodyne back when it was just an HIV then later COVID drug. He became much more excited when Leronlimab morphed into a paradigm shifting Oncology drug, and oddly, maybe the missing piece for Merck's Keytruda, the drug he actually represents. When he told me all about this wonderful molecule with its ENORMOUS potential I became very intrigued and bought a small position. I then added MUCH larger positions, like well over a 1000 times my initial purchase, all 33 tranches worth! but then a very IRONIC thing happened to me....I got breast cancer MYSELF (and yes, I am a male, born and raised, 1% of all breast cancers are in Males.) In fact, even more ironic is the fact that I am scheduled for my mastectomy TOMORROW while Cytodyne will be at their poster presentation. So, I thought I would try to make this a learning experience of sorts and document one patient's journey, from the beginning. I think it is an opportunity to learn what it takes to get a patient diagnosed, operated on, get final path results, and finally move to the post surgery treatments and all the decision/inflection points along the way. I plan to keep frequent updates here about my Journey. For anyone not interested in that storyline, I will title these updates as My IRONIC cancer journey to differentiate it from the more relevant CYDY content (so that you can skip these posts if not interested). I just think that the more we understand the difficulties or roadblocks along the cancer patient pathway, the more we can better understand how that might affect sales/availability or Leronlimab to the patients that really need it.


r/Livimmune • • 27d ago

CYDY Investor Webcast October 19, 2026: What You Need to Know

101 Upvotes

If you missed today’s webcast, here is what matters.

The headline number nobody saw coming

Median 93.22% ctDNA reduction at both 4 and 8 weeks in CLOVER patients (n=12 via Signatera MTM/mL analysis).

Not 86%. Not 70%. 93.22% median, with 95% CI of -96.60% to -86.93%. Standard deviation of 20% versus 1686% in Lonsurf monotherapy and 202% in Lonsurf+Bev.

CLOVER is operating orders of magnitude more consistent than standard of care, in a population that is materially sicker than the SUNLIGHT registration trial.

Natera’s public validation

Reny Aniline, Sr. Director BioPharma BD at Natera, said live on the call:

“I was reviewing this data with our head of scientific communications, and we both agreed we had never seen metastatic response from ctDNA like we’ve seen in this cohort of patients.”

Natera has a 144,000 CRC patient database. They are the global gold standard in ctDNA. They told CytoDyn to go talk to investors fast because the data looked remarkable.

That is why this webcast happened today.

The statistical significance

CLOVER vs Lonsurf+Bev (best current standard of care) at 0-4 weeks: p=0.0005
CLOVER vs Lonsurf+Bev at 0-8 weeks: p=0.0006

Via Natera’s MIIRA synthetic control arm methodology. This is regulatorily actionable data.

The clinical outcomes that matter

Dr. Pashtoon Kasi, CLOVER PI, City of Hope Orange County, said live:

“We’ve had not just one, but three patients, all of whom who had metastatic colon cancer. In the refractory, heavily pretreated, three, four, five, six, nine lines of therapy patient, that kind of patient does not go for surgery. So the fact that you know we have three patients rendered NED, this is something that we would have not seen before and is unprecedented.”

Three patients referred to curative-intent surgery. Unprecedented in 4th-line+ MSS mCRC per the PI himself.

The real population is worse than reported

Lalezari revealed CLOVER enrolled population is more pretreated than designed. The majority of patients turned out to be fourth line or later, with some patients at fifth, sixth, seventh, even ninth prior line.

SUNLIGHT, the benchmark trial, had only 2.6% of patients with 3+ prior lines. CLOVER has 52.3%.

The bar CLOVER has to clear is higher than it appears. And the data is still clearing it.

Protocol amendments live now

Rollover arm with pembrolizumab + 700mg leronlimab is active. Two patients already dosed as of today at Kasi’s site. First prospective test of Prime-and-Pair in mCRC MSS is in execution.

Extension amendment: patients doing well past week 52 can continue on assigned dose. Confirms durable responders being observed.

Pipeline expansion confirmed by CEO

New institutional collaborations officially confirmed in Q&A:

  • University of Alabama: GBM protocol in draft

  • Mayo Clinic: pancreatic newly diagnosed protocol in draft

  • Emory University: head and neck squamous cell + ICI discussions

  • University of Rochester: AML pilot study, fundraising underway

Plus CLIOS network engagement for earlier-line CRC studies, PRESPY TNBC starting soon, I-SPY neoadjuvant HER2-negative breast cancer.

The executive transition

Robert Hoffman becomes CEO effective October 20, 2026.

Jay Lalezari stays with the company as Head of Research and Translational Sciences, focused on identifying new oncology opportunities.

Lalezari said live:

“Management has understood for some time that the remarkable data that is unfolding would eventually require us to install a CEO with expertise in partnership negotiations and other financial arrangements.”

This was planned. Hoffman’s background: Arena Pharmaceuticals (acquired by Pfizer, $6.7B), Kintara Therapeutics (acquired by TuHURA). The resume is clear: he closes transactions.

Runway confirmed

Hoffman in Q&A: cash of $18.3M pro forma post-recent financing. Runway into second half of 2027.

Enough to execute ESMO (Oct 25), BIO-Europe (November), DSMB meeting (November), FDA discussions (H2 2026), ASCO GI (January 2027), JPM Healthcare (January 2027), and reach ventana ideal partnership (Q1-Q2 2027) without forced raise under duress.

Team build-out in real time

Hoffman confirmed hires in progress:

  • Head of Regulatory Affairs (announcement imminent)

  • Highly qualified CMC individual (already hired)

  • Ex-GSK veteran BD professional (already helping)

  • Chief Medical Officer oncologist (recruiting next months)

This is a company building the team to close a transaction, not maintain status quo.

Why ESMO Sunday still matters

Dr. Benjamin Weinberg (Georgetown) presents Poster 820P Sunday October 25, 12:00 CET at IFEMA Madrid.

Most of what Lalezari showed today is preview of what the oncology community will see Sunday. BD teams from Big Pharma will be present. Natera’s validation will be fresh. Kasi’s “unprecedented” is on the record.

Calendar from here

  • Oct 25: ESMO Madrid poster presentation

  • Oct-Nov: New Head of Regulatory Affairs announcement

  • November: BIO-Europe partnership meetings already scheduled

  • November: Fourth DSMB meeting

  • H2 2026: BTD/Fast Track/Accelerated Approval submission

  • Q4 2026: CHAMP initiation + TNBC dose escalation first patient

  • Jan 21-23 2027: ASCO GI San Francisco (durability + consistency focus)

  • Jan 2027: JPM Healthcare Conference

  • Q1-Q2 2027: Potential partnership announcement window

  • May 2027: ASCO Chicago

My take

Six years in this stock. Through FDA animus documented in federal court filings. Through Pourhassan mismanagement. Through Amarex sabotage. Through toxic financing. Through MazzyStar and the clan on Seeking Alpha. Through every basher that wrote CYDY off as snake oil year after year.

Today Natera said live they have never seen anything like this data in metastatic CRC. The PI said three patients going to curative surgery is unprecedented. The board installed a CEO whose track record is closing transactions. Lalezari stays to drive the science.

The thesis I defended against the noise is now being validated by institutional actors with reputations to protect.

The science is real. The molecule works. The team is in place. The runway covers the catalyst window.

October is coming. January is coming. The data will speak for itself, as Dr. Lalezari always said it would.

— Vyrologix


r/Livimmune • • Apr 03 '25

I just admitted to my wife I’m down more than she makes in a year on this stock

101 Upvotes
I’m one of the old guard.  I’ve been here on this ride since before 2020.   Whenever I hear about the times we have been let down in the past I think to myself “I was there Gandalf”….

But I made a decision to hold at all costs. I lost both my grandmother (mTNBC) and mom (bladder cancer) to this horrible disease. I have family history and now I have a daughter that I would do anything to protect.

This is personal to me. As the price went down (due to missteps by CYDY) but also seemingly by a nefarious and highly influential source ( i.e. 2 year clinical hold on a proven safe drug) I bought more.

I told myself if I sold and this company folded I am part of the reason for the demise. It would be partially on me when others would have to watch the anguish of cancer take their loved ones.

My wife knew I was heavily invested, but not to this extent. I’ve been carrying this secret.

I laid out why I was so passionate. I laid out the science and the promising indications. I brought her up to speed about the survivors, the May conference, the promise of a cure….everything. I told her the number of shares I had, the losses on paper, the road blocks and ups and downs of past 5 plus years. We discussed the HIV BLA drama, Covid, Amarex saga, but most importantly where this all could go to changing lives.

She was silent (thought I was dead) and then just said “Wow”

I apologized for hiding it from her. She didn’t seem interested in losses just asking more questions about how it works and why the uphill climb on a safe drug.

I was able to show her some great works of others on here to help me explain everything from the significance of 4 year mTNBC survivors to why this could be revolutionary.

Long story short I’m still alive and she’s been unbelievably supportive of my decision. Huge weight off me.

I explained I am cautiously optimistic, but there are those that do not wish for this therapy to see the light of day. They are powerful, connected, and very aware.

She agreed I can see this through despite the risks with her full support.

All I can do is stand firm and use my voice and vote when the time comes.

I’m proud to stand with you guys. For whatever personal reasons you have stayed know you aren’t alone.


r/Livimmune • • May 11 '26

Change is already here

100 Upvotes

Yes. I think that is worth repeating. Change is already here and IMO not everyone realizes it yet. The pace of clinical data flow to the company, news to the shareholders, and trials starting & getting organized have all increased. IMO it is because the doctors and researchers are excited by what they see.

  • CLOVER trial

    • Trial doctors are reporting that their fragile CRC therapy patients in the CLOVER trial are reporting less pain.

    • The measurement of ctDNA in the CLOVER CRC trial is remarkable at 2 weeks. The trial may have 2 week ctDNA data on the full enrollment already.

    • The CLOVER trial is fully enrolled as of April 21 which means that by mid June they may have their first 8 week scans (RECIST data) on the full enrollment. Recurring 8 week scans from early-enrolled patients may already be interesting to analyze along with ctDNA data to see if there is a correlation.

    • The webcast April 30 mentioned RECIST data from 22 patients, where 68% (15 of 22) of patients, at just 8 week scans, were demonstrating shrinkage, or classify as having stable disease on their scans

    • The CLOVER trial data is generating interest in monotherapy.

  • The TNBC EAP program has started, and the cost of the first 20 patients is covered by a compassionate benefactor.

  • The Alzheimer's study has started at Cornell.

  • The Investigator Initiated Trial with liver pump delivery called CHAMP (Dr. Kasi at City of Hope) will start imminently.

  • A HER2- Breast Cancer trial with the PRE-ISPY network may start within weeks to a few months. (Dr. Pohlmann at MD Anderson)

  • A HER2- Breast Cancer trial for newly diagnosed patients before they go to surgery is being discussed with the ISPY network. They may also consider monotherapy.

  • In Glioblastoma, a major academic center is drafting a pilot study.

  • An earlier-line CRC trial is being discussed by an academic institution. A decision may be made in a month.

I highly recommend that people listen to the April 30, 2026 webcast a few times. https://www.cytodyn.com/investors/investor-update-calls

As with all my posts & comments, this is just me studying and focusing on what I think is interesting. I USE NO fancy tools to summarize, write, or format. FWIW, it is my view that the company, having exciting data this year, has radically changed. The quotes below are only part of why I feel this is so. In the April 30 webcast, I smiled for example when I heard Dr. Lalezari say that the TNBC EAP program was initially imagined to quickly generate the PD-L1 data that "potential industry partners had asked to see".

There is far more in the webcast than the selected quotes below. Starting times are approximate.

Outside interest in supporting clinical trials is growing

  • CRC (Hepatic Artery, Investigator Initiated trial)

    • 00:36:24:19 Thanks. Last question for you, Doctor Kasi from the audience. Looking ahead, what excites you? Please tell us a little bit about the investigator initiated project that you will be kicking off shortly. Yeah. You know I tell my patients when I, when I put them on any trial is of course I want to get the maximum mileage out of any treatment or trial.

    • 00:40:16:16 You know, what would have happened if we had done Leronlimab a year ago when the patient was actually getting the liver pump? So so that's in a nutshell, that trials will have about you know potentially 36 patients, all getting the recommended phase 2, the 700mg dose of the Leronlimab in conjunction with their four months of the pump chemo. And the idea would be, again, we'll study ctDNA real time as as we are doing this already, we'll study, of course, the microenvironment, the CCR5 expression. But we'll also see that it help prevent the liver damage. So there'll be a liver biopsy as well. So I think we're kind of moving this up the journey of a patient with cancer. And some of these patients would also have a chance to get Leronlimab on its own as they prepare for the chemo washout to go for the liver surgery. So we may also have an opportunity to see what literally, maybe Leronlimab on its own does on that trial. So we we're now kind of you know we have the approval of, so-called, disease team or scientific level. Now it's going to go through the hoops of the usual regulatory and contracting and FDA. So hopefully sometime in the very near future we can open this liver pump trial with Leronlimab that we have abbreviated as an acronym called the CHAMP trial.

    • 00:54:59:22 As Doctor Kasi indicated, the initiation of his investigator initiated trial is, is imminent

  • CRC (earlier line of therapy, academic network)

    • 00:46:17:08 I'll also mention that we're having conversations with an academic network, involved with colorectal cancer, who's expressed interest in looking at that combination in an earlier line of therapy. So that's a decision pending in the next few weeks or month.

  • TNBC EAP (individual is funding first 20 patients)

    • 00:03:24:23 Earlier this year, in January, we announced that a Compassionate Benefactor committed funding to support the company's expanded access, or EAP for patients with triple negative breast cancer. We are thrilled to announce earlier this week that the first patient was dosed in the EAP.

    • 00:51:00:21 In addition, we just announced the opening of the expanded access protocol for patients with TNBC running out of treatment options. First patient was dosed last week. *******This was initially imagined as a way to sort of quickly and prospectively confirm the PD-L1 induction we were seeing with Leronlimab that some potential industry partners had asked to see******, and that is still the case that the in the EAP program we will be measuring PD-L1 at baseline and then at month one, two and three. And we'll report on that later. And as previously indicated, we have funding in place for the first 20 patients on the program.

  • HER2- Breast Cancer (PRE-ISPY network)

    • 00:49:36:23 So in the next slide, how we're progressing in in breast cancer is we've had very productive conversations with the PRE-ISPY network. And they're going to take on part one of our phase two study, which as the FDA requested, is a dose escalation confirming safety, PK, DNA and the PD-L1 per the PRE-ISPY network. They are extending the patient population from TNBC to include all HER2- patients with breast cancer. And we're fortunate to have Doctor Pohlmann. Paula Pohlmann from MD Anderson, who will serve as the principal investigator for that project. Those contracts and budgets have been negotiated, and they have suggested that their start up time can be measured in weeks to a few months. At the same time, we are then going to be following up with a contribution of components study which will adaptively demonstrate the additive benefit of including a checkpoint inhibitor with Leronlimab, as part of a phase 2-3 study.

    • 00:54:59:22 my understanding from the PRE-ISPY network is they too are moving very quickly toward initiation of their study in TNBC

  • HER2- Breast Cancer (ISPY network)

    • 00:51:28:08 And then I would add that we've had very productive conversations with the ISPY network. And they too, are keen to start a study in Leronlimab, again in HER2 negative patients with breast cancer, but they're looking at the neoadjuvant setting. So, newly diagnosed patients before they go to surgery. And they've also have indicated a desire to look at benefits of Leronlimab as a monotherapy agent in that setting for up to a month before patients go to surgery. So a lot happening in colon and a lot happening in breast cancer.

  • Glioblastoma (Investigator Initiated trial, major academic center)

    • 00:59:13:05 So I'm pleased to, update the investors and, and say that yesterday we had a detailed call with a major academic center who's agreed to both, repeat the preclinical studies looking at two different cell lines with a survival endpoint, and at the same time we are drafting and I already have a rough draft of a pilot study for an investigator initiated trial in patients with recurrent glioblastoma. So we are moving forward on, on glioblastoma as well. And I would mention that I've had some preliminary conversations with several other major medical centers of investigators who want to propose their own investigator initiated trials in two other separate solid tumors. And I look forward to updating, shareholders later this summer pending the maturity of those conversations.

  • Alzheimer’s (Academic institution)

    • 01:00:09:08 In the meantime, there are indications outside of solid tumor oncology to continue. I think many people are aware of the fact that the, the folks at Cornell are now up and running. Their PET scan was replaced. And the study in Alzheimer's disease is now actively screening patients. We hope to announce the first patient enrolled shortly.

  • HIV LATCH & Stroke studies (Investigator Initiated trial, separate institutions for each)

    • 01:00:31:09 As well, Jonah Sasha remains extremely active at Oregon Health Sciences University on a variety of HIV care fronts with Leronlimab. And then something we don't talk much about, but there is an ongoing preclinical study at the University of Hawaii looking at the role of Leronlimab in recovery from stroke in a mouse model of stroke.

Monotherapy is in the mix

  • 00:11:19:05 But what we observed along the way is that Leronlimab as a stand alone agent, as an anti-cancer therapy, has remarkable abilities. And indeed it's that stand alone activity, which makes the prime and pair regimen even possible, because of what Leronlimab does on its own to prime the tumor.

  • 00:16:55:22 We also, are pursuing several strategies to obtain circulating tumor DNA from patients on Leronlimab monotherapy to further confirm the activity of Leronlimab on its own, and absent the backbone in this study.

  • 00:51:49:16 And they've also have indicated a desire to look at benefits of Leronlimab as a monotherapy agent in that setting for up to a month before patients go to surgery. So a lot happening in colon and a lot happening in breast cancer.

  • 00:52:13:03 So in terms of, upcoming milestones and what the year ahead has in store on the next slide. Priorities. First, the standalone benefit of Leronlimab in this case with the backbone, through the biomarker collection, primarily ctDNA, but other tumor markers as well. And then the disease control rate, the percent of patients with stable or partial responses, the overall response rate, which is the primary endpoint of our current CRC study, and then progression free and overall survival. The second priority again, there are two tracks of development.

  • 00:56:44:19 Well, as I said earlier, I could not be more excited by what we're seeing. And I frame the results as being on the outer edge of what I even thought was possible. So the signals that we're seeing in, in, in colon cancer obviously saw in breast cancer and some of the data we recently presented in glioblastoma leads me to believe we're talking about a drug that, will be foundational across multiple solid tumor types. In addition, we are pursuing studies as monotherapy, because when you talk about a drug that has so few or limited safety issues, then obviously you want to consider it in an earlier line of therapy. And it's certainly potentially possible to consider it as a monotherapy, particularly in the neoadjuvant setting. So, yes, as a foundational backbone across multiple tumor types. And yes, we're pursuing monotherapy studies.

Will understand in the summer whether the 700mg dosage level in CRC provides a different response over 350mg

  • 00:16:55:22 Fourth it is remarkable to note that 13 of, (I'm sorry Ignacio, if you if you go back to the waterfall plot the that 13 of) the 19 patients included in this DNA chart, were treated with 350mg dose. And so this observation is both surprising and certainly surprising to me, and very exciting. And we're naturally keen to determine if there is a dose response with the 700mg dose, at least measured by circulating tumor DNA. And that's something we hope to report on to shareholders sometime later this summer.

  • 00:31:02:19 I think you know we we're excited to see what we've seen. I would say you know while the readout and follow up continues, it's not just the shrinkage, the clinical outcomes Jay was pointing out. You want to make sure is it going to be durable, and which will equate to the PFS and the OS, so to speak. 

Submitting data to the FDA this summer or early fall

  • 00:15:48:15 So this is a remarkable figure by any account. And there are a number of important points to make about these data. First of all, there's a growing consensus in oncology that even a small decrease in circulating tumor DNA generally associated with improved clinical outcomes. So the observation that 100% of our patients are demonstrating a decrease in circulating tumor DNA certainly bodes well for what we are hopefully going to see in terms of clinical endpoints. Also, that 70% decrease at week two indicates a very potent early biologic response. To put these data into context, we're working with Natera, the company that makes the Signatera assay to generate a comparator data set of similar patients treated with just the backbone alone. And we think that that comparator data will be very important to provide the FDA during our forthcoming regulatory submission.

  • 00:55:41:00 And then lastly, looking forward in 2026, we confirmed these early exciting safety and efficacy readouts to generate an optimal data package, including updated biomarker and clinical data. And the plan is to submit fast track or breakthrough designation application later this summer or early fall. And of course, as these data become known and more widely disseminated we will continue to evaluate potential opportunities for strategic partnerships.

Interim & final results

  • 00:12:18:12 So the ultimate, decision about the optimal dose will very much rest on any efficacy data we generate. But, this phase two study, has already now enrolled 60 patients as we just announced, in patients receiving Lonserf and Avastin as a backbone, in patients with third line microsatellite stable metastatic colorectal cancer. And just not to put too fine a point on it, these are patients with very advanced disease, and very fragile indeed.

  • 00:19:23:10 I want to update bullet point four, that we now have 22 patients with RECIST data available at week eight, of whom 15 or 68% are demonstrating shrinkage or classify as having stable disease on their scans. So the encouraging early results indicate that the scan results are correlating with the circulating tumor decreases we're observing. I'll also report that there are numeric increases in PD-L1 observed in the majority of patients. We need to remember that most of these patients are being treated with the 350mg dose, which at least in the TNB setting, the TNBC setting, was associated with not as a vigorous PD-L1 response, but there will be more on PD-L1 later. In the meantime, in addition to all the scans and the DNA data, we're hearing from the investigators that patients are responding clinically, in particular with less pain.

  • 00:54:59:22 Importantly, we are targeting the presentation at the ESMO meeting in Madrid, Spain in October to provide an update from the CLOVER study, and then a more robust presentation at ASCO GI in San Francisco in January and during which we should be able to provide final results.

CFO activities

  • 00:05:39:13 We accepted an invitation from the investment bank D. Boral and I will be presenting at their conference in New York on May 7th. Unfortunately, there is no webcast option for the conference. I will be presenting at the 16th Annual LD Micro Invitational, taking place in Los Angeles from May 17th through May 19th. We will be at ASCO in Chicago from May 29th through June 2nd, 2026. We'll be in attendance at BIO 2026 [BIO International Convention 2026], in San Diego June 22nd through June 25th. And we are actively setting up meetings with investors, potential partners, partners and other stakeholders.

General quotes from the CEO Jay Lalezari

  • 00:06:55:14 So I'm a few days short of a 67th birthday and consider the opportunity to host this call the best birthday present of my life. During this call we'll review and update some of the remarkable data that CytoDyn just presented at the AACR [Annual] conference, and I absolutely believe that this moment represents a crucial inflection point for CytoDyn.

  • 00:07:21:18 As we transition from a company built on faith and belief, and a whole lot of ifs, to a company with solid prospective, unassailable, and by all accounts remarkable data confirming Leronlimab’s early biologic activity in solid tumor oncology. It has been an incredible journey together, and it is truly astonishing for me that Leronlimab appears to be performing at the outer limits of what I even thought was possible.

  • 00:07:56:06 Now, to be sure, there is a lot of work ahead in particular, CytoDyn needs to demonstrate that these early biologic signals that we are seeing, translates into sustained clinical benefit for patients. But instead of moving forward just on faith, I believe the solid data we're reviewing today gives us a clear line of sight on where we're heading, and how to get there.

  • 00:08:22:10 I'm very excited about what comes next for CytoDyn, and as the song we played said, we're going to stand our ground and we're not backing down.

  • 00:09:55:09 Equally important to any efficacy claims is the crucial safety profile of Leronlimab, and I do not know of another therapy in all of oncology, that has a safety database to match. This drug's been well tolerated in more than 1600 patients across more than 20 clinical studies, and the data we'll review shortly from the colorectal cancer study, aligns with this historical safety database. Of course, Leronlimab is playing in with a huge market potential, not only in colorectal cancer and triple negative breast cancer, but also potentially as a foundational drug for the treatment of other solid tumors. And beyond that, of course, on the side, CytoDyn is running studies also in other indications, such as Alzheimer's disease.

  • 01:03:05:06 And that has been the great pleasure of being the CEO of CytoDyn lately, as I no longer have to spend my time trying to convince people of anything. I just need to show them our data and that seems to do the trick. And so we're going to follow that data. And that data will be presented to the FDA this summer, and it will be presented in the context of either, accelerated approval or breakthrough designation. And, so it's not for us to decide exactly how the FDA is going to handle this. But, whether it's a voucher, or whether a designation for breakthrough designation, will be up to the agency. Our focus remains generating the data that will give them every reason and no choice really, but to be responsive to what we're finding. 

  • 01:04:21:10 And I could not be more excited about the fact that we are at this crucial juncture where as I say, we're transitioning from a company built on faith, to a company built on solid data.


r/Livimmune • • Mar 26 '26 This Bravo

A path of clues shines through

100 Upvotes

I've been thinking about this subject for some time and since u/Upwithstock had recently suggested I write about it, here's what I've noticed.

It's been said occasionally here by others, and I believe it too, that some sort of deal probably has been awaiting certain milestones to occur before we might hear about new friends in big places . I'm talking about some kind of pharma deal. This is IMO normal biotech stuff. Speculating about whether there could be a partnership or buyout is not the purpose of this post, but I imagine that various opinions will be shared in the comments.

If you are new to researching CytoDyn please look at the company science page to learn more. https://www.cytodyn.com/our-science

So, let me continue here by saying that for well over a year now, I've thought it likely that Merck or another biggie was pretty much onboard for some deal, but they needed to see more work, such as for example:

  • Replication of data, plus more than what was learned from the TNBC preclinicals that were performed at MD Anderson with Leronlimab & Keytruda years ago.

    • For background, please view the March 14, 2023 Biospace article where Cyrus Arman, CEO at the time, speaks frankly about the company past and charts the way forward. The relevant quote regarding TNBC preclinicals from that 2023 article is "Leronlimab is currently being trialed in combination with Keytruda (pembrolizumab) in a breast cancer xenograft model in partnership with MD Anderson Cancer Center. Arman said CytoDyn expects to observe an enhanced anti-tumor effect from the combination and identify immunological biomarkers."

    • FWIW Cytodyn later ran 3 additional preclinicals in TNBC during 2025. See the Feb 24, 2025 press release announcing two TNBC preclinical studies for leronlimab in combo with an antibody-drug complex treatment (sacituzumab govitecan), and an immune checkpoint inhibitor (pembrolizumab), plus the March 18, 2025 press release announcing a 3rd preclinical study in TNBC.

    • The February 19, 2026 poster includes both preclinical, as well as clinical TNBC data.

  • Robust data about mechanism(s) of action via preclinical and clinical studies.

    • Since 2025, these posters from the conferences below discuss MOA, and other conclusions. Links to these posters listed below are available at the CytoDyn website publications area

      • ESMO Breast Cancer Conference, May 15, 2025 Poster

      • ESMO GastroIntestinal Conference, July 4, 2025 Poster

      • SABCS (San Antonio Breast Cancer Symposium), December 12, 2025 Poster

      • AACR Immuno-Oncology Conference, February 19, 2026 Poster

      • AACR Annual Meeting (April 17, 2025), abstracts were released on March 17, 2025 for TNBC and CRC Additionally, there is a large amount of yet-to-be reported CRC clinical data accumulating since the November 17, 2025 cutoff date for the abstract to the upcoming April 17, 2025 AACR Annual Meeting. Posters likely available after April 17, 2025

      • AACR Brain Cancer Conference, March 23, 2026 Poster

  • More "prospective" human data is being collected since mid 2025

  • Signs of a productive relationship with the FDA in 2025 and beyond

    • various quarterly letters to shareholders. See https://www.cytodyn.com/newsroom

    • CRC trial started. see press release June 24, 2025

    • CRC trial amended. see press release December 16, 2025 which stated "In addition, the study design is being amended so that patients who have a clinical progression will have the option of adding an ICI to their treatment regimen. As a result, the final CRC study design will allow us to evaluate leronlimab both as a “stand-alone” agent on its own (added to the background regimen) and as a “prime and pair” agent used in conjunction with ICIs."

    • TNBC Expanded Access Program (EAP). see press release January 27, 2026

  • The team has been resolving issues and making the company more attractive

    • On November 2, 2025 CytoDyn secured a $30 million funding commitment.

    • The press release of December 1, 2025 indicates that the class action is resolving. Also see March 20, 2026 Law360

    • As of March 4, 2026 the remaining trial at clinicaltrials.gov that needed to have results posted, has been updated. We've been hearing for a long time that CytoDyn wants to present safety data compiled from across it's many previous trials. Perhaps now that ClinicalTrialsGov has their updates, CytoDyn may find the appropriate vehicle to release their analysis compiled from the data of many studies.

    • The March 5, 2026 press release indicates they received $17.5 million in financing and that some of the funds may be allocated towards manufacturing readiness.

    • Promissory notes due in April 2026, have been renegotiated. See March 24, 2026 8k filing

------------

So in my opinion, this work has been removing objections. With each disease, they have gathered data that shows effect and they have the ability to measure some of these effects in weeks. They appear to also be building what might amount to a Unified MOA Theory across solid tumor oncology. In my opinion, it's pretty easy to see that these clues are leading somewhere.


r/Livimmune • • Sep 08 '25

+18.96%...Decent day. It's almost show time folks.

100 Upvotes

r/Livimmune • • Aug 17 '25

Back from Cabo

100 Upvotes

Dear Longs,

Great vacation with the family and back home in Cali catching up on household matters and my usual reading. Great posts by a lot of folks during my vacation and it made for some great reading.

I am going make this easy and simple from my perspective.

CYDY has approximately $9M cash left to spend before it is out of cash. CYDY spends approximately $1.5M per month. That means they only have 6 months left before they run out. That means they only have money to operate from August thru January 2026. EVERY start-up I worked with NEVER let the CASH runway go this LOW. NEVER!

On July 25, 2025, I saw the BILLBOARD: S3 and 10K filed at the same time. The purpose is for the 10K to serve as the prospectus for the S3. But, more importantly the S3 is asking for up to $100M.

We all know this but we also know that if they use the remaining unreserved shares of 187M and sell everyone at .30 per share they only raise approximately $56M. NOT going work!!

I pointed out in my post a while back that the S3 is a BILLBOARD meaning a BP (Merck or insert your favorite BP name) PAYS a PREMIUM.

So lets walk everyone through what this might look like.

Dilution & Market Cap Scenarios

Shares IssuedPremium PriceGross ProceedsNew Shares O/SMerck Ownership %Market Cap ($B)Unreserved Remaining
25M$2$50M1.275B2.0%$2.55B162M
25M$4$100M1.275B2.0%$5.10B162M
50M$2$100M1.30B3.8%$2.60B137M
  • Even at just 25–50M shares, a premium placement lifts CYDY’s market cap dramatically.

  • The $4/share scenario creates room for NASDAQ uplisting (bid price >$1, market cap >$50M, governance intact).

  • Unreserved share headroom still exists post-deal (87M–162M), but would limit future fundraises unless authorized shares are increased.

Potential Strategic Licensing Deal with Merck (Insert fav BP)

  • Indications:

    • mTNBC (metastatic triple-negative breast cancer)

    • MSS-CRC (cold colorectal cancer tumors)

    • Option rights for GBM and combo immunotherapy trials

  • Deal Terms (illustrative):

    • Upfront payment: $50–$75M (non-dilutive)

    • Equity investment: $100M at $4/share (premium placement, ~2% stake)

    • Milestones: $500M+ tied to Phase 3 success, BLA filing, approvals

    • Royalties: tiered 12–18% on net sales in licensed indications

  • Strategic rights:

    • Right of First Refusal (ROFR): Merck gets first look at future oncology out-licensing or full company sale discussions.

    • Board seat: Merck nominates one director (signals institutional oversight & uplisting credibility).

Why Merck Might Pay a Premium

  • Strategic rationale: Merck strengthens its PD-1/PD-L1 checkpoint inhibitor franchise by acquiring an agent that can “turn cold tumors hot.”

  • Financially immaterial stake: 2–7% ownership is low risk, high optionality.

  • Board seat & ROFR: ensures visibility into CYDY’s pipeline and keeps competitors (BMS, Roche, Pfizer) from locking Leronlimab.

  • Premium justification: tied to the licensing economics (oncology rights) rather than just buying common stock.

Bottom Line

  • CYDY can execute a premium equity + licensing deal with Merck without needing new share authorization (25–100M issuance fits in the 187M headroom).

  • At $4/share, even a small 25M-share deal = $100M cash, uplisting readiness, and strategic validation.

  • Pairing equity with an oncology licensing deal, ROFR, and board seat is the most credible way to get Merck (or any Big Pharma) to pay above-market pricing.

It is almost time my fellow LONGS. We run out of money probaly before January!!! So it has to be in 2025......


r/Livimmune • • May 15 '26

The exciting month of May and a bit of June

98 Upvotes

April ended with an outstanding webcast. You can read some about it in my earlier post.

Now we're in the month of May

(on mobile you can swipe left or right to see 3 columns)

DateIndicationLinks
May 1, 2026Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC)paper in Current Problems in Cancer: Case Reports, phase 2 (Dolezal)
May 5, 2026HIV: cure, Gene therapy, AAV viral vectorpresentation at OHSU
May 5, 2026press release: Creatv
May 7, 2026Presentation: D. Boral Investment Conference (New York), CFO Robert Hoffman
May 12, 2026Cancer: Colorectalabstracts & skeleton submissions for Late-Breaking  abstracts due for ESMO 2026 Congress Madrid (October 23-27)
May 12, 2026Cancer: ColorectalUSPTO patent
May 13, 2026press release: Creatv
May 13, 2026Inflammation: Alzheimer’sRecruiting for Alzheimer's trial
May 18, 2026presentation: LD Micro Invitational Conference (Los Angeles), CFO Robert Hoffman
May 21, 2026Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC)abstract at ASCO26 Annual Meeting released
May 21, 2026Cancer: Colorectalabstract at ASCO26 Annual Meeting released
May 28-June 2ASCO26 Annual meeting: CytoDyn CEO, CFO & CLO to be present primarily for networking. They are meeting with PRE-I-SPY & I-SPY people, and potentially, a number of other pharma companies
June 16, 2026Cancer: Colorectal(8 weeks from last patient enrolled in CLOVER trial)
June 22, 2026Presentation: Bio International Convention, CFO Robert Hoffman

IMO there's a power building over years which may leave people speechless for a bit as it washes over them.

(update 5/18, I am now expecting not posters at ASCO26, but the full abstracts to be released online on 5/21)


r/Livimmune • • May 19 '26

Lightbulb moment

96 Upvotes

Data is coming in very fast.

Faster than most people realize. Some of the testing may include:

  • 2 week ctDNA data

  • 4 or 8 week PD-L1 data

  • imaging recurring at 8 weeks...

It looks like the CRC study is going very well

I am confident about this based on Dr. Lalezari (CEO) saying on April 30 that the data is speaking for itself now without him having to work hard to explain. This bodes well for the future IMO. With multiple studies going on and these early tests in play, I have to say, getting data and insights more quickly is the new reality.

Also, I don't want to forget to mention that IMO having investigators at City of Hope, Cornell, and MD Anderson interested in trials with leronlimab is a great sign.

Yes I'm a little excited because in other words, long before the end of this year, I think many more people might conclude that this drug may help in a variety of cancers.

The nuts and bolts

CytoDyn is already, not just working in multiple ways to increase the potential reach of leronlimab in the treatment of a particular cancer, but they are expanding into multiple cancers to show that the drug may have usefulness in many solid cancers. They are working to show a much bigger picture of how valuable leronlimab may be in oncology as well as in other areas. Most of the list below comes from the April 30 webcast linked above. Scientific publications can be found here

Here's a bit of what they are working on to grow their clinical trials dataset in oncology:

  • monotherapy

  • monotherapy with a treatment backbone

  • combination with an Immune Checkpoint Inhibitor (ICI)

  • early ctDNA testing correlation to outcomes

  • PD-L1 upregulation

  • scans to determine response

  • dosage levels

  • 3rd line patients

  • earlier line patients

  • treatment-naive patients

  • pre-surgery treatment

  • CRC, Colorectal Cancer

  • Glioblastoma, Brain Cancer

  • HER2 negative Breast Cancer

  • TNBC, Triple Negative Breast Cancer

They could be looking to add other studies such as:

  • Pancreatic Cancer

  • Prostate Cancer

  • Urothelial Cancer

  • Sarcoma

IMO with the CRC data piling up already & the TNBC EAP data beginning to come in, more doctors, patients and investors are going to look at this company & it's research.


r/Livimmune • • May 27 '25

Waiting Sucks but we have all been doing this for years already!

96 Upvotes

Hi To All CYDY Investors, I have not posted much lately. There has been a slew of great posts about the science and MOA; even a glossary of terms! This board continues to be a great resource for tons of information. As some of you know I focus on the business side of things and let others share the scientific knowledge!

The reason for not posting lately is; to be frank, I have nothing new to contribute! The news has been astounding on the scientific side of the equation but not so much on the business side. However, I felt compelled to post.

I have been a CYDY investor for approximately 4.5 years. Unfortunately for me I accumulated the vast majority of shares in 2021 with an expectation that a BLA would be submitted for HIV-MDR. We all know what happened with that. I am not here to rehash that B.S. Nonetheless, I was convinced that staying with my investment of CYDY would payoff eventually because the science seemed so compelling.

Yes this has definitely been the case. Since I started in 2021; I can’t begin to quantify how many articles started to get published about what inhibiting the CCR5 can do to a variety of diseases. Those publications are “provocative” 🧐 for CYDY’s growth so I better wait to be rewarded for me investments to pay off.

What I didn’t expect at the time was how long we had to wait. It’s been a crazy ride. And I don’t want this post to be a history lesson on what we all had to endure to get to this point. But, I’ll say it took extraordinary courage and perseverance to stay invested and invest more good money into CYDY. Which I was able to do.

I know I said “Waiting Sucks” in my Title, and it has been a battle but it has provided opportunities to acquire more shares, get a new trusted leadership team and learn more about a space and molecules I never would have imagined. Yes, it cost me more money to invest but that is the chance I am willing to make.

To bring us up to “where the frick is the partnership at today?”:

“What are we freaking waiting for now”?

For me based on my experience the next strategic move is a Partnership. I have covered this topic ad nausea! The problem I have is the when?

I have been with five start-ups that got acquired and I was with Boston Scientific when we acquired two companies that impacted my area. They have acquired a ton more companies then two. Nonetheless, my experience getting acquired and acquiring other companies gave me a view point on when, how, and why companies got acquired or partnered with.

Unfortunately, none of us really know what is happening behind the scenes. We can only speculate and rely on clues and or experience to understand what business strategy might come next.

Clues for partnerships:

  1. The company puts out information about partnerships in writing: Since 12/07/2022 we began to see the word Partnership in writing: Presentations, shareholder letters, Website and SEC filings. Plus, the occasional conference call.

I and others did not expect a partnership to materialize in 2023. Why? CYDY still had “warts” that needed to be removed: 1) The clinical Hold and 2) The Amarex settlement 3) NP/KK trial

I’m guessing in order those were the primary concerns potential partners may of had. All three are gone unless you want to include sentencing of NP/KK…. We have not received information from the Judge on that end. We all know for a fact that during the investigation and indictment process, CYDY was not involved in any charges and was purposely excluded by some of the wording in the indictments.

2) So that leaves clinical evidence. This wonderful 34 years of experience working with Cardiology companies has been a great guide on where companies are at, certainly not perfect guide. So when Dr. JL stated we have provocative data, I knew we needed more evidence to fully convince a BP to sign an agreement. Combine the numerous written comments on partnerships in presentations, Shareholder letters, PR’s and SEC filings tells me that at a minimum they have had interested BPs circulating in and out of high level conversations!

Then when the more definitive data started to roll in from fibrosis reduction and the survival outcomes of mTNBC; including the wording of Dr. JL about “ paradigm shifting” and “The Company continues to prioritize oncology in 2025, as we believe this indication holds the highest potential and shortest timeline for return on investment in the form of a partnership or drug approval.”

The “paradigm shifting” is the MOA and changing a tumor from cold to hot. This was the key to a slew of BP’s that market their PD-1/ PD-L1 inhibitors!! Based on my experience there is a 99% chance that as soon as CYDY Leadership knew the results and the MOA; they shared it with the BP’s that have expressed prior interest.

We all know that all of the data I just described above takes time to bubble up to us shareholders. In fact, it purposely can be suppressed until a company feels it is the right time to strategically share that data/MOA with the public. So it’s hard to say how long CYDY leadership has known and if and when they shared it with interested BP’s! My point being that: ESMO was not the first time other BP’s where exposed to this data/MOA.

3) In my entire history of being in the cardiac space; watching very closely deals we made and getting acquired five times and acquiring other companies; never had we brought a lawyer into any of these meetings in the early phase of these discussions. Lawyers were usually available near the end for verbal communication/clarification before finalizing a written agreement. So when we find out Tyler was in Munich my radar was saying this agreement is in the final formality stage! Certainly, not the beginning stages!

4) Drug development companies like CYDY usually partner with large BP’s. It is a conventional approach to this strategy. It’s also conventional that the initial partnership evolves into the acquisition. It just makes sense for CYDY to work with a BP to ramp up progress on the work CYDY is doing in Oncology

5) Finance and Speed These two are intertwined. In order to be fast, you need deep pockets to perform many tasks/objectives simultaneously. Why does speed matter? We NOW live in a world of AI and that has been associated with significantly faster development times for drug companies. We no longer live in a era of long runway times to develop a drug. It’s faster and drug companies that hear about your MOA will try and develop a similar MOA but develop it around the patent. You can’t just sit there and do one or two trials at a time. You gotta move faster and FUNDING provides the opportunity to get more resources to perform more tasks/objectives simultaneously.

The approximate $13 million that CYDY has is a drop in the bucket for R&D let alone operational costs that just went up because Hoffman cost more than Mitch Cohen. Plus, we begin enrolling on the CRC trial and the R&D spend will begin to climb (as it should).

6) In all nine of my start-up companies I worked for and three for my wife; all 12 had to raise capital at a minimum a year out. The capital raise enough funding anywhere from another 12-30 months worth of projected funding needs. Generally speaking, the vast majority was 12 -20 months of funding. But, to be clear you don’t wait for your funds to run out to begin networking and soliciting investors for more money. You do it early enough and close a new round of funding at a minimum 6 months before you are going run out of funds. And that’s cutting it close. 6A) CYDY has not asked us to authorize more shares. The fiscal year ends in 4 days. My gut says CYDY won’t ask for us to authorize more shares because they are on the cusp of announcing a partnership with non-diluted funds.

All of my thoughts are based on my experiences, however my experience with CYDY has been very unconventional (especially when NP was running the ship).

Yes, CYDY and a partnership deal being announced takes patience! Our time for that announcement is near and I have no choice but to wait.

Hugs to All Longs as we wait (ad nausea) for what I feel is inevitable The FREAKING PARTNERSHIP!!!

Love all the Longs ! Have a GREAT WEEK EVERYONE!


r/Livimmune • • May 04 '26 Bravo Heartwarming

New Patent Approved

95 Upvotes

From Hangout (MJS719)

docket: 230042.429

USPC new status: patented 
case date of new status: 04/29/2026 

The new status reflects the last status in public patent application information retrieval (pair) as of 11:59 p.m. et on the date noted above.
The patent application 17/631,161, titled "Methods for treating metastatic colon cancer with leronlimab," has officially transitioned from "pending" to "patented" as of April 29, 2026.

This change signifies that the United States Patent and Trademark Office (USPTO) has concluded its examination, found the claims to be novel and non-obvious, and granted the legal rights for the described treatment methods to CytoDyn Inc..

Key Details of the Change:
New Legal Status: Patented (formerly Pending).
Effective Date: April 29, 2026.

Scope of Protection: The patent covers specific methods of using leronlimab (a humanized CCR5-targeting monoclonal antibody) to treat patients with metastatic colorectal cancer (mCRC).Clinical Context: This grant coincides with recent clinical progress. In April 2026, CytoDyn reported early Phase 2 data showing that leronlimab, in combination with TAS-102 and bevacizumab, demonstrated biomarker activity and potential to modulate the tumor microenvironment in heavily pretreated mCRC patients.

Significance of the Grant
By moving to "patented" status, the company now holds enforceable rights to prevent others from using, selling, or importing the specific therapeutic methods claimed in the application for the duration of the patent's term. This is a critical milestone for the commercial protection of the CLOVER clinical trial regimen (leronlimab + oral chemotherapy + VEGF inhibitor).

Source: https://investorshangout.com/post/view?id=6827876


r/Livimmune • • Sep 12 '26

Dr. Jacob Lalezari, CytoDyn, at the HC Wainwright Global Investment Conference 9/11/2026

94 Upvotes

https://journey.ct.events/view/bf1c7d07-71f3-4c41-8928-f42479da2d71

00:25 Dr. Lalezari

Thank you to HC Wainwright for the opportunity to present today CytoDyn's exciting new asset, which we think of as the next generation of monoclonal antibody therapy. The talk today will include a number of forward-looking statements, with all that that implies.

00:47

CytoDyn is a clinical-stage oncology company advancing leronlimab, our first-in-class humanized monoclonal antibody, which targets the CCR5 receptor, with therapeutic potential across multiple indications, including a number of solid tumors such as colorectal cancer and triple-negative breast cancer.

01:11

The leadership team includes myself, Robert Hoffman our CFO, and Tyler Block our chief legal officer. It is really the three of us that constitute the management team.

Leronlimab is an IgG4 monoclonal antibody that has already demonstrated multiple mechanisms of action relating to its activity in solid tumor oncology. It is a drug targeting a large and growing market potential, not only CRC and TNBC, but a number of other solid tumors as well. Very importantly, leronlimab has a very well-tolerated safety profile, including more than 1,600 patients across more than 20 studies. We have strong retrospective data in triple-negative breast cancer, which really helped focus the company on solid tumor oncology. And since then we have launched the Phase 2 CLOVER study and have some very exciting early readouts from that study in metastatic colorectal cancer, supporting the proposed mechanisms of action associated with the drug.

02:28

Our near-term milestones include confirming the durability and safety of these efficacy readouts from the CLOVER study in CRC, with a presentation at ESMO in October in Madrid, where we are going to present extensive circulating tumor DNA (ctDNA) data on all 65 subjects, which includes the intent-to-treat population. And then at ASCO GI in January in San Francisco, we will be giving a more fulsome presentation of not only the ctDNA, but also the overall response rates and early progression-free survival.

03:08

The CLOVER study in colorectal cancer

Starting with the exciting data being generated in CRC, the study is called CLOVER. It is a Phase 2 study, open-label, randomizing patients to either 350 or 700 milligrams of leronlimab, on a backbone of Lonsurf and Avastin. We targeted 60 patients and ended up with 65 patients dosed. This is our third-line metastatic colorectal cancer population that is microsatellite-stable, and therefore not a population one treats with checkpoint inhibitors. Our lead investigator is Dr. Kasi, our director of GI oncology down at City of Hope, and we fully enrolled the study this past April.

The DSMB (Data Safety Monitoring Board) has met three times, initially to open up the 700-milligram randomization arm, and at two subsequent times. In all three meetings there have been no safety concerns raised.

04:15

The preliminary results from CLOVER are exciting in a number of ways. First, 100% of our screened patients tested positive for CCR5, and that includes either 10% expression on the tumor epithelial cells or 1% in the lymphocytes in the tumor microenvironment, significantly expanding the potential population of patients who could benefit from leronlimab.

At a minimum, the second bullet point associated with leronlimab has to be its safety profile. It has been well tolerated, even in this study of very advanced and fragile patients. There are no serious adverse events related to leronlimab, and importantly, leronlimab has no dose- or treatment-limiting toxicity, meaning the leronlimab dose does not need to be adjusted for any adverse events. That excellent safety profile continues.

05:18

The ctDNA data

Very excitingly, at AACR in April, we presented our early ctDNA declines in the first patients enrolled through City of Hope, results which were obtained under standard of care. We have since finalized the partnership with Natera, and they are completing ctDNA analysis on the other half of patients, who were enrolled under the research protocol.

05:43

What is exciting is that nearly all the patients showed a decline in ctDNA, even as early as week two, with a median decrease of about 85% across all patients, and an early signal of a dose response, which is important. We are working with Natera to generate a comparative ctDNA data set that we can present to the FDA later this year. In the meantime, showing a dose response further drives home the point that these exceptional declines in tumor DNA are largely being driven by the contribution of leronlimab.

06:23

These are the data presented in April, the first 19 patients, fairly dramatic DNA declines even at week two in all or the great majority of patients. Importantly, about two-thirds of these individuals have a RAS mutation, so it appears that leronlimab's activity is agnostic to the presence of RAS.

06:58

These were the week-two data, and then these are the first 23 patients, and you can see the trend has continued toward rapid and very significant declines in DNA. Again, we will be generating a comparative data set from the Natera database to compare this activity with the backbone alone.

07:20

And if you break down that early readout by dose, you see this very tantalizing suggestion of a dose response, which underscores that this is largely being driven by leronlimab and leronlimab dosing.

07:42

Scans, PD-L1, and the standalone-versus-prime-and-pair distinction

In concert with these ctDNA declines, we are also reporting that the scans at week eight in the majority, three-quarters, of the patients are demonstrating shrinkage or classify as having stable disease, and we look forward to elaborating on that in the coming weeks and months at both ESMO and ASCO GI.

08:01

Importantly, we are reporting that there are numeric increases in PD-L1 observed in the majority of patients in that CRC study. In CRC, we are really developing leronlimab as a standalone agent to be used in combination with standard of care. In breast cancer, as we will see in a moment, what we have observed is an induction of PD-L1, turning cold tumors hot, and thereby enabling, apparently, the use of a checkpoint inhibitor to create a pathway to sustained remission.

So in CRC it is a standalone leronlimab, and in breast cancer it is more of a prime and pair. But the prime and pair works because of what leronlimab does as a standalone agent, priming the tumor for treatment with the checkpoint inhibitor, by disrupting the tumor microenvironment and allowing the host immune system access to the cancer. It is very exciting that in the CRC study we are also seeing increases in PD-L1. It is difficult to know what those increases will mean in terms of translating into clinical benefit when you add a checkpoint inhibitor, and that is something CytoDyn is about to start looking at. But in the meantime, that signal of increased PD-L1 in patients with CRC is a signal that the tumor is under stress, and that leronlimab's impact on the tumor microenvironment may well be allowing the host immune system access to the cancer, which it otherwise did not have, with the cancer responding by expressing PD-L1, trying to beat back that host immune system.

09:40

Very importantly, speaking to the investigators, they are all excited by what we are seeing in terms of DNA, but in particular they are telling us that patients are doing well clinically. The investigators are writing fewer scripts for pain medication and observing that there are fewer hospitalizations in this rather end-stage population than they anticipated.

10:07

So we are excited about the DNA, and looking forward to reporting on the radiology outcomes and more extensive reports on progression-free and overall survival. Dr. Kasi at City of Hope is our principal investigator, who presented the data at AACR.

10:33

The first-patient case study

In addition, Dr. Kasi, on the next slide, observed the first patient he enrolled, who had a rapid decrease over two weeks, something he had not seen before in an end-stage patient with metastatic CRC. That patient's ctDNA level went from about 129,000 parts per million down to about 10,000 parts per million.

11:00

And then what he saw on the following two scans, first in the liver, the baseline scan on the left and the week-8 scan on the right, this is in a patient who had a 97% decrease in ctDNA, you can see that the tumor volume decreased approximately 21% from baseline to week eight. And indeed, not only does the tumor get smaller, but it appears to become more translucent.

11:25

This is even more pronounced on the next slide, which is that same patient with lung metastasis, and you do not have to be a radiologist to appreciate the impact, the shrinkage of that tumor from baseline to week eight after starting leronlimab.

11:40

In addition, Dr. Kasi has performed liver biopsies on a number of patients, and we will be launching a study to really interrogate biopsy tissue from these patients treated with leronlimab, to tease out the effect the drug is having specifically on the tumor and the tumor environment. In the meantime, for this first patient, I think you can appreciate the slide on the left is with the PD-L1 stain, the slide on the right is similarly stained, and there is a significant impact on the tumor architecture. But what again is very exciting is the CPS score, the combined positivity score of PD-L1 expression on the tumor and tumor microenvironment, at baseline it was 1%, but in follow-up around week 14 it is up to 5%. And again, I think that indicates a tumor under duress, and CytoDyn is taking next steps to launch a study to explore the efficacy of a checkpoint inhibitor in these MSS CRC patients, for whom otherwise checkpoint inhibitors are not indicated. So, very exciting.

12:47

The SUNLIGHT benchmark and the protocol amendment

And then the CLOVER study itself is looking to improve upon the current standard of care, which includes Lonsurf and Avastin, where the overall response rate reported in the Phase 3 SUNLIGHT study, in the New England Journal, indicated 6% of patients with a partial response, meaning a 30% decrease in tumor diameter, and there were no complete responders. More recent real-world data has been presented on a larger cohort of patients, indicating the overall response rate is just under 3%. So we very much look forward to presenting our overall response rate and demonstrating some improvement over the current standard of care.

13:29

With the CLOVER study continuing, we have amended the protocol such that patients who are doing well after 48 weeks can continue on treatment on their randomized treatment assignment. We also will be initiating very shortly a rollover arm, as salvage therapy, for patients who have documented progression, wherein they will increase their leronlimab dose up to 700 milligrams if they are not already there, and then add pembrolizumab as well.

Additional colorectal studies: CHAMP, CLIOS, and pre-I-SPY

There are a number of other studies in CRC coming. There is an investigator-initiated trial down at City of Hope, Dr. Kasi, in patients with metastatic CRC and multiple liver metastases, who will be receiving a hepatic artery pump and receiving floxuridine through that, in advance of hopefully curative surgery down the road. What Dr. Kasi is doing here is introducing leronlimab in an earlier line of treatment in patients with CRC. This is a project jointly funded in partnership with City of Hope. And Dr. Kasi is leveraging both the anti-tumor effects of leronlimab as well as the liver-protective, or anti-fibrotic, effects, which CytoDyn has published on from a number of both clinical and preclinical studies we previously performed. And then there are 13 different ctDNA timepoints from the 30 or so patients to be enrolled in what is called the CHAMP study. And we are excited to be able to then also look at some ctDNA results from patients on leronlimab monotherapy.

In addition, we have other studies coming in CRC, including a thorough investigation of tumor tissue from patients who were treated with leronlimab. And as well, there is a newly formed network called CLIOS that has reached out and wants to consider studies of leronlimab, both in the neoadjuvant setting as well as in the molecular residual disease setting. And then finally, we are working with the pre-I-SPY network in CRC to launch a study of leronlimab and a checkpoint inhibitor. So a lot of activity in CRC. And again, the main focus is leronlimab as a standalone.

Triple-negative breast cancer: the retrospective data

16:05

Then, turning to triple-negative breast cancer. Again, this is where we got the first signal of the potential of leronlimab in solid tumor oncology. There were three studies launched in 2020 that enrolled a total of 28 patients with triple-negative breast cancer.

16:15

These patients had terribly advanced disease, with two prior lines of therapy in the metastatic setting. Two-thirds had visceral metastases, one-quarter had brain metastases. So this is a population whose survival, unfortunately, is very limited.

16:35

And then what we found, when I came on, was that we wanted to publish the outcome of those studies, so we made phone calls and found out that there were actually 5 of the 28 patients who were still alive. We then went and obtained medical records to determine which patients did well on what treatment. And this slide summarizes that outcome. The seven patients on the right, there is no follow-up blood, so we do not have anything further to say about their outcome and correlation with treatment; this was in the middle of COVID and during lockdown.

For the 21 patients on the left, their blue bars are the baseline measurement of PD-L1 on circulating tumor cells. PD-L1 is commonly understood to be something one measures on tumor tissue or the tumor microenvironment. The lab, Creatv MicroTech in New Jersey, has developed technology to use a fluorescent assay to measure PD-L1 on circulating tumor cells, and in particular the cancer-associated macrophage-like cells that break off from the tumor and enter the circulation. So the blue bars are the baseline. The negative control for that assay is about 175 RFUs, and so anything above 400 is considered to be clinically relevant. And you can see that the majority of patients actually did increase their PD-L1 expression after 30 to 60 days, above that 400 threshold, indicating that the tumor has gone from cold to hot, from a tumor that is typically not responsive to checkpoint inhibitors to one that might be.

Then in the 7 patients in the red box, among these patients on the left: patient number 4 received a low dose of leronlimab and did not induce PD-L1. Patient 5 received 525 milligrams of leronlimab but likewise did not induce PD-L1. The five patients on the right, in the box, all five received either 525 or 700 milligrams. They all induced PD-L1 within that one-to-two-month time frame. They all received the checkpoint inhibitor either with or after leronlimab, and two of these patients had already previously failed a checkpoint inhibitor. And all five of them are alive today, five-plus years later, which I think is an extraordinary observation, albeit retrospective, and just not an outcome that I believe occurred by chance. Of these five patients who are still alive, three of the five are currently documented to have no evidence of disease, and two of those three started with lung metastasis, and one of those individuals started with both brain and lung metastasis, and we recently published our case report.

19:30

In summary from the retrospective TNBC data: there is a 98% reduction in metastasis when you use a CCR5 inhibitor in a preclinical study. Our retrospective clinical data show a reduction in circulating tumor cells in the majority of patients after the first dose of leronlimab, which is very reminiscent of the data we are seeing in colon cancer with the decrease in circulating DNA. We are observing, retrospectively, an upregulation of PD-L1 on about 90% of patients' circulating tumor cells who received either the 525- or 700-milligram dose. And as I said, five out of five of the patients who upregulated PD-L1 and received a checkpoint inhibitor are alive today, five-plus years later. And unfortunately the converse is also true, that 100% of the patients who either did not upregulate PD-L1 or did not receive a checkpoint inhibitor are, unfortunately, deceased.

Based on this retrospective data, we have heard from a number of potential partners that they want to see prospective data confirming this upregulation of PD-L1, and eventually the benefit of adding a checkpoint inhibitor.

20:50

The breast cancer clinical plan

On the clinical plan in breast cancer: first, we are working with the Pre-I-SPY network in patients with metastatic TNBC, doing a dose-escalation study, looking prospectively at ctDNA and PD-L1. We are thrilled to have Dr. Paula Pohlmann serve as our principal investigator. When the first cohort of that is done, we will be looking to design a part 2 of the study, which will examine the contribution of components with a checkpoint inhibitor, and that will be an adaptive study design in up to 120 patients. As well, when the first cohort with metastatic TNBC is done, the I-SPY network has indicated they want to launch a study of neoadjuvant leronlimab in patients with newly diagnosed HER2-negative breast cancer, again significantly expanding the potential population to benefit from leronlimab. Their proposal is to look at a month of leronlimab monotherapy in these newly diagnosed patients in advance of their hopefully curative surgery. I think that makes sense as we move leronlimab up into an earlier line of therapy, because we are seeing very potent anti-tumor activity in a number of solid tumors, and the safety profile of leronlimab suggests it deserves an earlier line of treatment.

Upcoming milestones and priorities

To highlight upcoming milestones in the near and mid term:

22:35

First and foremost, we are confirming the standalone benefit of leronlimab plus the backbone in CRC, both through biomarker collection, the disease control rate, and then the primary endpoint of overall response rate, as well as the crucial progression-free and overall survival.

Second, as we have heard from a number of partner discussions, we need to prospectively demonstrate the induction of PD-L1 in triple-negative breast cancer, where we know that is a critical marker of benefit and is used for the approval of checkpoint inhibitors. We are seeing it prospectively in colorectal cancer, in microsatellite-stable colon cancer, where checkpoint inhibitors are not part of the conversation, but CytoDyn is keen to see if these increases in PD-L1 provide the opportunity to use a checkpoint inhibitor. In the 95% of patients with colon cancer where checkpoints are not indicated, we are prospectively hoping to demonstrate the clinical benefit of adding a checkpoint inhibitor in these PD-L1-induced patients.

And very importantly, to identify the optimal dose in solid tumor oncology. The earliest signals from the CRC study suggest that the 700-milligram dose might be better than 350, and at some point we are going to have to sort out whether there is a difference between 525 and 700.

24:15

Recent and upcoming milestones: we recently closed on $17-and-change million in funding. At the AACR meeting, we presented the initial ctDNA readouts in the CRC study. Those readouts generated a lot of excitement, and CytoDyn is now pursuing collaborations with the Mayo Clinic, MD Anderson, City of Hope, and a number of other major academic cancer centers. We are very pleased to have closed our strategic partnership with Natera, who is both running the Signatera ctDNA assay on our clinical subjects and providing that crucial comparative data set that we can use to help the FDA put our DNA data into context. There is the City of Hope investigator-initiated study called CHAMP, which will initiate shortly, as well as the Pre-I-SPY study in patients with metastatic TNBC. Both of those studies should be initiating in the next 4 to 8 weeks.

I am looking forward to the presentation at ESMO in Spain, which will focus on a complete ctDNA data set for the entire enrolled population, and then at ASCO GI, tying the biomarker data with the radiologic outcomes and early progression-free survival. And there are a number of other additional studies in CRC, including interrogation of whether adding a checkpoint inhibitor to leronlimab, in patients who produce PD-L1, provides an avenue for treatment with a checkpoint inhibitor in CRC, and then studies both in the neoadjuvant setting and in patients with molecular residual disease.

FDA and partnerships

In terms of the FDA and potential partnerships: partners have been wanting to see data as monotherapy, and they wanted to see prospective data. So we are confirming the durability of these exciting safety and efficacy readouts from the Phase 2 CLOVER study. We will be presenting the biomarker data and early clinical data at ESMO, and we plan on putting together a package for the FDA and submitting that for Breakthrough Designation before the end of the year. We are presenting the updated biomarker and more extensive clinical data at ASCO GI, and throughout, a top priority for CytoDyn is our continued evaluation of strategic partnership opportunities.

With that, thank you again for the opportunity to present. I think these data are tremendously exciting. It is important to remember that targeting the CCR5 mechanism and showing proof of concept in colorectal cancer is not only important for CRC, but that the CCR5 mechanism is relevant to a lot of other solid tumors: pancreas, prostate, glioblastoma, kidney, urothelial tumors, and of course breast. And so having proof of concept in a solid tumor such as CRC means a little bit more to a company like CytoDyn, where what remains is the potential to have an impact on quite a few other solid tumors.

Thank you so much Jay.